Modulação do ciclo TG/(GL+FFA) como alvo terapêutico na obesidade by Silva, Maria Helena Almeida Braz da
 
 
   
Universidade de Aveiro 
2014 
Departamento de Biologia 
Maria Helena Almeida Braz 
da Silva 
Modulation of TG/(GL+FFA) cycle as a 
therapeutic strategy in obesity 
Modulação do ciclo TG/(GL+FFA) como 
alvo terapêutico na obesidade 
 
 
 
 
 
 
 
  
 
 
DECLARAÇÃO 
  
 
  
Declaro que este relatório é integralmente da minha autoria, 
estando devidamente referenciadas as fontes e obras 
consultadas, bem como identificadas de modo claro as 
citações dessas obras. Não contém, por isso, qualquer tipo 
de plágio quer de textos publicados, qualquer que seja o 
meio dessa publicação, incluindo meios eletrónicos, quer de 
trabalhos académicos. 
 
  
 
 
 
  
 
 
  
Maria Helena Almeida Braz 
da Silva 
Universidade de Aveiro 
2014 
Departamento de Biologia 
Dissertação apresentada à Universidade de Aveiro para 
cumprimento dos requisitos necessários à obtenção do grau 
de Mestre em Biologia Molecular e Celular realizada sob a 
orientação científica da Doutora Anabela Pinto Rolo, 
Professora Auxiliar do Departamento de Biologia da 
Universidade de Aveiro, e sob a co-orientação científica do 
Doutor João Paulo Soeiro Terra Teodoro, Investigador de 
Pós-Doutoramento do Centro de Neurociências e Biologia 
Celular da Universidade de Coimbra. 
Modulation of TG/ (GL+FFA) cycle as a 
therapeutic strategy to obesity 
Modulação do ciclo TG/ (GL+ FFA) como 
alvo terapêutico na obesidade 
 
 
  
 
 
  
                           Aos meus pais.  
Por todo o amor, amizade e apoio incondicional. Por todos os 
ensinamentos que formaram os alicerces da minha vida. Sem 
vocês nada disto seria possível.  
 
 
 
  
 
 
  
o júri 
 
presidente Professora Doutora Maria de Lourdes Pereira 
Professora associada com agregação no Departamento de Biologia da Universidade de Aveiro 
Professor Doutor Carlos Manuel Marques Palmeira 
Professor Catedrático do Departamento de Ciências da Vida da Faculdade de Ciências e Tecnologia da 
Universidade de Coimbra 
Professora Doutora Anabela Pinto Rolo 
Professora Auxiliar do Departamento de Biologia da Universidade de Aveiro 
 
 
  
 
 
  
Em primeiro lugar, gostaria de agradecer ao Professor Doutor 
Carlos Palmeira e à minha orientadora Professora Doutora Anabela Rolo 
por esta oportunidade, pela confiança depositada neste trabalho, por todos 
os ensinamentos, pela orientação e toda a disponibilidade! Obrigada 
também pela amizade, simpatia e carinho com que me receberam no 
MitoLab! 
 
Ao Doutor João Soeiro, o meu co-orientador pela amizade, 
disponibilidade, apoio e por todos os conselhos e sugestões feitas ao longo 
deste trabalho. 
 
À Faculdade de Ciências e Tecnologia da Universidade de Coimbra 
e ao Centro de Neurociências e Biologia Celular, pelo acolhimento. 
 
Ao Professor Doutor Rui de Carvalho e ao Laboratório de 
Ressonância Magnética Nuclear da Universidade de Coimbra, pela grande 
(enorme!) ajuda na análise dos espectros de ressonância magnética 
nuclear.  
 
Aos meus colegas de laboratório, por toda ajuda, paciência e 
sobretudo amizade! Por me fazerem sorrir todos os dias e sentir como se 
sempre tivesse feito parte do MitoLab! Obrigada: Ana, Catarina, Filipe, Inês, 
João, Leka, Rui e Rute! 
 
 À Inês, pela amizade, ajuda e muita paciência ao longo deste 
trabalho. Obrigada pelo grande impulso inicial! Foi um prazer trabalhar 
contigo. 
 
 A todos os meus colegas, amigos e companheiros que foram 
deixando a sua marca ao longo da minha vida, fazendo de mim uma pessoa 
melhor! 
 
Ao Tiago. Por ter sido a chave de todo o incentivo e força nos 
momentos mais difíceis. Por todo o amor, amizade e companheirismo. 
Meine liebe, Ich liebe dich! 
 
Aos meus avós, por fazerem parte do meu mundo, por todo o amor, 
carinho, amizade e suporte ao longo da minha vida. Levo-vos sempre no 
meu coração! 
 
E por fim, um obrigado do fundo do coração aos meus pais. Não há 
palavras que descrevam o amor que sinto por vocês. Obrigada por fazerem 
de mim aquilo que sou hoje. Esta conquista é igualmente vossa! 
 
agradecimentos 
 
 
  
 
 
  
palavras-chave 
 
resumo 
CDCA, Ciclo TG/ (GL+FFA), Obesidade, Adipócitos 3T3-L1, UCP-1, 
Mitocôndria 
A obesidade é um dos principais problemas de saúde pública a nível mundial. 
A grande maioria da população obesa desenvolve patologias associadas que 
consequentemente levam à diminuição da esperança média de vida. Estas 
incluem diabetes tipo 2 (T2DM), aterosclerose, esteatose hepática, doenças 
cardiovasculares e ainda alguns tipos de cancro, Dado que as estratégias 
atuais são ainda pouco eficazes, no que se refere ao tratamento da obesidade, 
é urgente que se investiguem novas terapias, nomeadamente a modulação do 
tecido adiposo branco (WAT). No WAT, as vias metabólicas da glicose e dos 
lípidos convergem no ciclo dos glicerolípidos/ácidos gordos livres (TG/ 
(GL+FFA)), sendo este considerado um ciclo fútil dado que não gera produtos 
enquanto consome substratos energéticos. A diminuição da atividade deste 
ciclo em situações de obesidade e diabetes diminui a oxidação de substratos e 
aumenta o armazenamento de ácidos gordos (FFA) no WAT. Assim, a 
estimulação deste ciclo fútil surge como um potencial alvo terapêutico. Porém, 
a oxidação de substratos implica a estimulação simultânea do ciclo fútil e da 
função mitocondrial sendo que, até à data, não existe um mecanismo capaz de 
acoplar estes processos. O ácido quenodesoxicólico (CDCA) é um ácido biliar 
conhecido pelos seus efeitos anti-obesidade, no entanto, o seu mecanismo de 
ação é ainda controverso. O CDCA activa dois reguladores da transcrição de 
genes metabólicos envolvidos no ciclo TG/ (GL+FFA), na capacidade oxidativa 
mitocondrial e na β-oxidação, o PPARα e o PPARγ. Assim, a nossa hipótese 
propõe que o CDCA medeia o acoplamento do ciclo fútil com o gasto 
energético no WAT, aumentando simultaneamente as taxas de atividade do 
ciclo fútil e de oxidação mitocondrial de substratos.  
Este trabalho foca-se na avaliação das alterações metabólicas no ciclo TG/ 
(GL+FFA), na linha celular 3T3-L1, induzidas pelo CDCA. Especificamente, 
avaliou-se se a exposição ao CDCA altera a atividade deste ciclo, se essa 
alteração está relacionada com uma melhoria no perfil metabólico e ainda se o 
metabolismo mitocondrial está envolvido. 
As células expostas ao CDCA demonstraram uma diminuição na acumulação 
de lípidos e um aumento no conteúdo de proteína desacopladora-1 (UCP-1), o 
que por sua vez diminui a produção de espécies reactivas de oxigénio (ROS). 
Adicionalmente, a exposição ao CDCA induziu um aumento na 
gliceroneógenese, sugerindo, assim, um aumento na atividade do ciclo TG/ 
(GL+FFA). Dessa forma, a administração de CDCA parece ser uma estratégia 
terapêutica atrativa no combate à obesidade e à T2DM. No entanto, uma 
questão mantém-se, o que leva à redução da acumulação dos triglicerídeos 
(TG)? Com base nos resultados obtidos, o CDCA aumenta a expressão dos 
genes envolvidos na β-oxidação e na biogénese mitocondrial, mas não existem 
diferenças na oxidação dos FFA entre o controlo e as células expostas ao 
CDCA. Uma possível explicação é que os lípidos estejam a ser exportados 
para o meio. No entanto, este é um estudo in vitro, logo seria interessante 
perceber o destino destes lípidos in vivo. Finalmente a possível ocorrência de 
compartimentalização metabólica abre novas perspectivas para trabalhos 
futuros.  
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abstract Obesity is one of the leading causes of health care issues all over the world. A 
large slice of the worldwide population develops co-morbidities as a 
consequence of this condition, such as type 2 diabetes mellitus (T2DM), 
atherosclerosis, fatty liver, cardiovascular diseases and even some cancers, 
conditions that are associated with reduced life expectancy. The inefficiency of 
current therapies that aim to treat obesity leads to further investigation on novel 
therapeutic targets for this condition, including modulation of white adipose 
tissue (WAT). In WAT, glucose and lipid metabolism  converge  into triglyceride/ 
glycerol + free fatty acid (TG/ (GL + FFA))  cycle,  which is  considered  a futile  
cycle  since  it  doesn’t  generate  products  while  consuming  energy 
substrates.  The decreased activity of this cycle in obesity, decreases 
substrates oxidation and increases free fatty acids (FFA) storage in WAT. If 
coupled to increased mitochondrial β-oxidation, modulation of TG/ (GL+FFA) 
cycling provides an attractive therapeutic target to stimulate fat mobilization and 
prevent WAT dysfunction. Currently there are no known strategies that 
simultaneously stimulate both these processes. Chenodeoxycholic acid (CDCA) 
is a bile acid known for its anti-obesity effects; however the mechanism of 
action is still controversial. CDCA activates both peroxisome proliferator 
activating receptor (PPAR) α and PPARγ, regulators of the transcription of key 
metabolic genes involved in the TG/ ( GL+FFA) cycle, mitochondrial oxidative 
capacity and FFA oxidation.  As  such,  we hypothesized that CDCA mediates 
the coupling of futile cycles with energy expenditure in  WAT,  increasing  
simultaneously  futile  acid  activity  and  mitochondrial substrates oxidation.  
This work focused on evaluating the metabolic alterations of TG/ (GL+FFA) 
cycle, in culture 3T3-L1 cells exposed to CDCA. Specifically, we addressed if 
CDCA supplementation alters the TG/ (GL+FFA) cycle activity, if this was 
related to improved metabolic status and if mitochondrial metabolism was 
involved. 
Cultured 3T3-L1 cells exposed to CDCA exhibit decreased lipid accumulation 
and an increase in uncoupling protein-1 (UCP-1) content, which in turn leads to 
a decrease in reactive oxygen species (ROS) generation. CDCA also leads to 
an increase in glyceroneogenesis, suggesting an increase activity in TG/ 
(GL+FFA) cycle activity. Indeed, these results show that administration of 
CDCA seems to be an attractive therapy to obesity and T2DM.  However, a 
question still remains, what leads to a reduction in triglycerides (TG) 
accumulation? Based on our results CDCA up-regulates genes involved in β-
oxidation and mitochondrial biogenesis, but there are no differences in fatty 
acid oxidation between control and cell exposed to CDCA. A possible 
explanation is that lipids are being exported to the medium. However this is an 
in vitro study, it would be interesting understand the destination of this lipids in 
vivo. Finally the possible occurrence of metabolic compartmentalization opens 
new perspectives in futures works. 
 
CDCA, TG/ (GL+FFA) cycle, Obesity, 3T3-L1 adipocytes, UCP-1, 
mitochondria 
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1. General Introduction 
1.1 Obesity 
1.1.1 An overview 
Obesity is one of the leading causes of health care issues all over the world. 
According to World Health Organization (WHO), 205 million men and 297 million women 
over the age of 20 were obese in 2008, a total of more than half a billion adults worldwide 
(Soumaya, 2012; WHO, 2013). As such, it is safe to claim that we are in the midst of a 
worldwide epidemic of obesity. 
One of the parameters for defining over-weightiness is the Body Mass Index (BMI), 
which is a measure of weight corrected for height and which reflects the total body fat 
(Nammi et al., 2004).  
 
The WHO defines that a BMI equal or greater than 25 indicates excess of weight 
and a BMI equal or greater than 30 is considered obesity (WHO, 2013). 
Several co-morbidities develop as a consequence of obesity like dyslipidemia, 
insulin resistance, type 2 diabetes mellitus (T2DM), atherosclerosis, fatty liver, 
cardiovascular diseases and even some cancers, conditions that are associated with 
reduced life expectancy (Scarpellini & Tack, 2012; Gesta et al., 2007). Obesity is also 
associated with metabolic syndrome, a cluster of disorders that require the presence of 
diabetes, impaired glucose tolerance (IGT), impaired fasting glucose or insulin resistance 
and any two of the following abnormalities: central obesity, dyslipidemia (high triglycerides 
or low high-density lipoprotein (HDL) cholesterol concentration), elevated blood pressure, 
or microalbuminuria (WHO, 1999). 
 Obesity is a multi-factorial disorder that involves complex ethological links 
between genetic, metabolic and neural frameworks on one hand, and behavior, food 
habits, physical activity and socio-cultural factors on the other (Nammi et al., 2004). In 
general, obesity is caused by energy imbalance, where energy intake exceeds energy 
expenditure for an extended period of time. This excess of energy intake compared to 
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energy usage leads to excessive accumulation of fat in adipose tissue, resulting in 
enlarged and/or increased number of fat cells (Bray, 2004; Sikaris, 2004; Nammi et al., 
2004).  
Fat distribution is a key to the development of metabolic syndrome, as shown in 
Figure 1. Increased intra-abdominal/visceral fat (central or apple-shaped obesity) 
promotes a high risk of metabolic syndrome, whereas increased subcutaneous fat in the 
thighs and hips (peripheral or pear-shaped obesity) exerts little risk (Gesta et al., 2007). 
 
´ 
Adipose tissue not only serves to store energy but is also one of the body‟s largest 
endocrine organs, affecting the function of cells and tissues throughout the body 
(Scarpellini & Tack, 2012). The excess adiposity and adipocyte dysfunction, leads to the 
dysregulation of expression of bioactive substances secreted by adipocytes, called 
adipokines. Adipokines, such as leptin, adiponectin, resistin, retinol protein binding 4 
(RPB-4), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), to name a few, can 
either promote inflammation and metabolic dysfunctions, or contribute to the resolution of 
both these processes (Scarpellini & Tack, 2012). The imbalance of pro and anti-
inflammatory adipokines is an important contributor to a chronic low-grade inflammatory 
state that has been associated to obesity (Scarpellini & Tack, 2012).  
While on one hand, lipid storage is increased in obesity, the adipose tissue 
inflamed also releases more free fatty acids (FFA) that lead to fat accumulation in liver and 
muscle, contributing to insulin resistance (Rasouli & Kern, 2008; Guan et al., 2002a). 
Figure 1 - Fat Distribution Influences risk of deveploment of metabolic syndrome. Adapted 
from Stephane Gesta et al. 2007 
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The glycerolipid/free fatty acid (TG/GL+FFA) cycle is associated with the flux of 
FFA in the organism. This process is intimately related with glyceroneogenesis, which 
rate-limiting step is regulated by phosphoenolpyruvate carboxykinase (PEPCK). In 
adipose tissue, glyceroneogenesis controlled by PEPCK contributes to the regulation of 
FFA release to the blood (Hsieh et al., 2011). The over-expression of PEPCK in white 
adipose tissue (WAT) lead to an increase of FFA re-esterification in adipose tissue and to 
obesity without insulin resistance (Franckhauser et al., 2002). The increased 
glyceroneogenesis reduced the availability of FFA to the muscle and thus prevented 
impaired glucose tolerance. Therefore, the regulation of (TG/GL+FFA) cycle seems to be 
important in the development of obesity and T2DM, and for this reason an attractive 
therapeutic target.  
Taking into account these findings, obesity and associated conditions are linked to 
disorders in the metabolism of glucose, which in turn are closely related with disturbances 
in the metabolism of lipids.  Since adipose tissue plays a crucial role in the regulation of 
fatty acid homeostasis, this organ may be a primary site where the early metabolic 
disturbances leading to the development of insulin resistance take place, followed by the 
development of insulin resistance in other tissues follows (Cahová et al., 2007). 
 
1.1.2 Regulation of glucose and lipid metabolism 
Obesity and associated pathologies are characterized by an unbalance in 
carbohydrate and lipid metabolism (Saltiel, 2001). Insulin and glucagon act in concert to 
ensure that glucose homeostasis is maintained throughout a wide variety of physiological 
conditions (Vance, 2002). Insulin stimulates glucose uptake, utilization, and storage, while 
suppressing hepatic glucose production, thus reducing plasma glucose levels (Prentki & 
Madiraju, 2012). Glucagon promotes the release of stored and newly synthesized glucose 
into the bloodstream. Pancreatic β and α-cells regulate insulin and glucagon synthesis 
and release, respectively, even in response to small changes in plasma glucose levels, 
since they are extremely sensitive to glucose concentrations (Hsieh et al., 2011).  
Following a meal, most glucose disposal occurs in skeletal muscle, whereas 
fasting plasma glucose levels are determined primarily by glucose output from the liver. 
The balance between the utilization and production of glucose is maintained at equilibrium 
by two opposing hormones, insulin and glucagon (Saltiel, 2001). After a meal, in response 
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to an elevation in plasma glucose and amino acids, insulin is released from the β-cells of 
the islets of Langerhans in the pancreas. The β-cells contain a specific glucokinase that 
exhibits a low affinity for glucose, and is not inhibited by product formation, thus enabling 
the enzyme to adjust its activity in response to a wide range of glucose concentrations 
(Prentki & Madiraju, 2012). After phosphorylation, glucose is oxidized and adenosine 
triphosphate/adenosine diphosphate (ATP/ADP) ratio increase, this leads to close 
potassium channels and consequently the cell becomes depolarized. This results in the 
opening of voltage-sensitive calcium channels, which increases intracellular calcium and 
insulin is released (Saltiel, 2001). During fasting or exercise, when plasma glucose level 
falls, glucagon is secreted by α-cells, which surround the β-cells in the pancreas. 
Glucagon promotes the release of stored and newly synthesized glucose into the 
bloodstream.  
The primary targets for insulin are skeletal and cardiac muscle, adipose tissue and 
liver. Glucose uptake is the rate-limiting step in glucose utilization and storage. Insulin 
stimulates the transport of glucose into muscle and fat cells by increasing the 
concentration of glucose transporter 4 protein (GLUT4) at the cell surface (Vance, 2002). 
Upon entering the muscle cell, glucose is rapidly phosphorylated by hexokinase and either 
subsequently stored as glycogen due to the activation of glycogen synthase, or oxidized 
to generate ATP synthesis, via activation of enzymes such as pyruvate kinase (Saltiel, 
2001). In adipocytes, glucose is stored primarily as lipid, due to increased uptake of 
glucose and activation of enzymes associated with lipogenesis. Insulin also inhibits 
lipolysis in adipocytes, primarily through inhibition of the enzyme hormone sensitive lipase 
(HSL) (Vance, 2002). Insulin inhibits the production and release of glucose by the liver, 
due to the blockade of gluconeogenesis and glyceroneogenesis. In addition to controlling 
the activities of metabolic enzymes through phosphorylation or dephosphorylation, insulin 
also regulates the expression of a number of genes encoding hepatic enzymes. On the 
other hand, glucagon increases hepatic cyclic AMP (cAMP), which in turn increases 
PEPCK gene expression during hypoglycemia. This results in augment rate of 
gluconeogenesis and glyceroneogesis that lead to an increase in plasma glucose levels 
(Franckhauser et al., 2002; Vance, 2002).  
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1.1.3 Metabolic imbalance associated with obesity 
Insulin resistance, the failure to respond to normal circulating concentrations of 
insulin, is a common state associated with obesity and T2DM. When the effects induced 
by normal or elevated insulin levels are attenuated, β-cell secretion increase to maintain 
normal blood glucose levels, and so insulin resistance is associated with compensatory 
hyperinsulinaemia (Reaven, 2004). 
A complex interaction between genetic and environmental factors underlies the 
development of insulin resistance, which affects whole-body metabolic homeostasis, with 
manifestations varying according to the dependence of the tissues on insulin for metabolic 
processes. Resistance to the antilipolytic effects of insulin causes increased lipolysis and 
FFA release from fat depots (Saltiel, 2001). This elevated plasma FFA attenuate the 
ability of insulin to suppress glucose production in the liver, but allow a continual increase 
in insulin-stimulated FFA synthesis. Initially, β-cell insulin secretion is also stimulated by 
elevated FFA, however, long-term exposure of pancreatic β-cells to elevated FFA 
ultimately impairs insulin secretion (Hsieh et al., 2011). Increased circulating levels of FFA 
are initially associated with increased rates of fatty acid oxidation in the skeletal muscle. 
However, the accumulation of metabolites from fatty acid oxidation in the cytoplasm of 
muscle cells (lipotoxicity) interferes with insulin signaling cascade and the ability to easily 
switch between glucose and fat oxidation in response to homeostatic signals (Hsieh et al., 
2011). For example, increased generation of nicotinamide adenine dinucleotide (NADH), 
and ATP inhibit key regulatory enzymes in the glycolytic pathway such as pyruvate 
dehydrogenase complex (PDC), contributing to increased blood glucose concentration. 
The augment of FFA oxidation also blocks the recycling of GLUT4 to the surface of 
muscle cells and decreases glucose uptake, thus contributing to increased blood glucose 
levels (Hsieh et al., 2011). 
The impaired uptake of glucose increases plasma glucose concentration leading to 
further insulin secretion and starting a vicious cycle with impaired regulation of energy 
substrate metabolism. This state of “metabolic inflexibility”, is defined as an impaired 
ability to switch easily between glucose and fat oxidation according to the metabolic needs 
of the organism (Cahová et al., 2007); (Saltiel, 2001) (Figure 2). 
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Figure 2 - Metabolic staging of T2DM. Adapated from Alan R. Saltiel 2001  
T2DM is characterized by a progressive decrease in insulin action, followed by an inability of the β-cell to 
compensate for insulin resistance. Insulin resistance is the first lesion due to metabolic changes produced by 
obesity. Insulin resistance in visceral fat leads to increased fatty acid production, which exacerbates insulin 
resistance in liver and muscle. The β-cell compensates for insulin resistance by secreting more insulin. 
Ultimately, the β-cell can no longer compensate, leading to impaired glucose tolerance, and diabetes. 
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1.2 Adipose Tissue 
 
1.2.1 Structure and physiologic function  
Adipose tissue is a dynamic organ at the center of nutritional adaptation and 
metabolic regulation (Sethi & Vidal-puig, 2007; Harwood, 2012). In mammals, adipose 
tissue exists in many different locations through the body and typically in areas of lose 
connective tissue, such as subcutaneous layers between muscle and dermis. Moreover, 
adipose-specific depots surround vital organs like heart and kidneys (Casteilla et al., 
2008).  
The classical roles of adipose tissue are to insulate the body, provide mechanical 
support and to store FFA after food intake, which are also released during the fasting 
state to maintain energy levels (Hajer et al., 2008).  
There are two types of adipose tissue: WAT and brown adipose tissue (BAT) 
(Figure 4). WAT constitutes the major component of body‟s adipose tissue and is 
responsible for the storage of energy in large unilocular droplets (mainly constituted by 
TG) and the release of FFA. Several types of cells constitute WAT: mature adipocytes and 
a variety of other cells (i.e., preadipocytes, fibroblasts, endothelial cells, and 
macrophages), usually described as the “stroma vascular fraction”. The adipocytes, 
preadipocytes, and macrophages have metabolic and inflammatory functions, which 
render WAT able to release several adipokines with effects on WAT and other tissues and 
metabolic processes, as described in previous section and as illustrated in Figure 3.                                                   
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In general, obesity is accompanied by an increased release of FFA and plasma concentration levels of 
adipokines (Leptin, Resistin and Retinol protein binding-4), with the exception of adiponectin, which plasma 
levels are lower. This rise on the level of adipokines leads to a chronic inflammatory state and insulin 
resistance in peripheral tissues, accompanied by infiltration of a large number of macrophages Although the 
majority of adipokines is adipocyte-derived, there are others which are also produced by macrophages (TNF-α 
and IL-6), interacting in a paracrine way to control adipocyte metabolism. 
 
Unlike WAT, BAT typically has a smaller number of adipocytes, which are 
multilocular, containing many cytoplasmic lipid droplets of varying sizes. BAT also has a 
richer vascular supplies with more abundant mitochondrial chromogens, responsible for 
the brown color (Sethi & Vidal-puig, 2007; Medina-gómez, 2012; Torres et al., 2008; 
Gesta et al., 2007; Redinger, 2009; Balistreri et al., 2010). BAT is considered a 
thermogenic tissue, with its specialized heat production through mitochondrial 
“uncoupling” of oxidative phosphorylation, by the action of uncoupling protein 1 (UCP-1). 
BAT mitochondria are enriched in UCP-1, while it is minimally present in WAT (Yehuda-
shnaidman et al., 2010). UCP-1 is present on the internal mitochondrial membrane and 
creates a proton leak that diminishes the electrochemical gradient needed for oxidative 
phosphorylation. As a consequence, BAT affects energy use by producing heat from 
uncoupled oxidative phosphorylation (Sethi & Vidal-puig, 2007; Medina-gómez, 2012; 
Torres et al., 2008; Gesta et al., 2007; Redinger, 2009; Balistreri et al., 2010). 
In humans, BAT was thought not to be present postnatally, but recently studies 
using positron emission tomography have clearly shown active BAT depots in adult 
humans metabolically, in the cervical, supraclavicular, axillary and paraventral regions 
(Yoneshiro et al., 2013; Lichtenbelt et al., 2009; Taittonen et al., 2009). 
Figure 3 - Obesity-induced changes in adipokine secretion and leads to the development of insulin 
resistance. Adapted from Galic et al. 2009 
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Recently, the concept of two distinct forms of adipose tissue has also been 
challenged through the recognition, in mouse and humans, that some fat depots have 
both white and brown adipocytes, and by the identification of a third form of fat cell, the 
“brite” (or beige) adipocyte. These “brite” (from the joining of the words “brown” and 
“white”) cells express UCP-1, but do not possess the complete molecular characteristics 
of brown adipocytes (Barbatelli et al., 2010; Wu et al., 2012; Petrovic et al., 2010). In 
humans, the amount of BAT is inversely correlated with BMI, so the conversion of white 
adipocytes into-“brite”-cells associated with their activation seems to be an attractive 
strategy to increase energy expenditure and reduce obesity (Wu et al., 2012).  
 
1.2.2 Adipogenesis 
Adipogenesis is the formation of adipocyte from precursor cells, as shown in 
Figure 5. Hormonal activity and transcription factors induce proliferation and differentiation 
of preadipocytes into mature adipocytes. In humans, preadipocytes are converted into 
adipocytes in the late embryonic stage origin. However, the ability of differentiation of 
Figure 4 - Distribution of the WAT and BAT depots. Adapted from Stephane Gesta et al. 
2007 
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preadipocytes is always present in all species depending on the body energy status and 
the storage needs (Torres et al., 2008; Moreno-Navarrete & Fernández-real, 2012).   
Development of adipocytes has been studied using two distinct cell lines. One 
refers to pluripotential fibroblasts that originate myocytes, chondrocytes and adipocytes. 
The other is a unipotential cell line (3T3-L1 origin) that can only give rise to mature 
adipocytes (Ntambi & Kim, 2000). Before converting into adipocytes, 3T3-L1 cells are 
maintained undifferentiated by the preadipocyte factor 1 (Pref-1) (Sul et al., 2000). When 
the differentiation program is initiated, CCAAT enhancer binding proteins (C/EBP-β/δ) 
expression is mildly increased. These are key early regulators of adipogenesis and 
promoters of the genes encoding C/EBP-α and Peroxisome Proliferator Activating 
Receptor Gamma (PPARγ), critical factors that maintain the phenotype of the adipocyte 
inducing the expression of genes involved in insulin sensitivity, lipogenesis and lipolysis, 
including those encoding GLUT4, fatty-acid-binding protein (FABP4, also known as 
adipocyte protein 2, aP2), lipoprotein lipase (LPL), perilipin and the secreted factors 
adiponectin and leptin (Lowe et al., 2011). Furthermore, differentiation of adipocytes is 
accompanied by an increase in the expression of sterol regulatory element binding protein 
(SREBP-1). SREBP-1 is a transcription factor that participates in adipocyte differentiation 
by stimulating PPARγ expression. The role of SREBP-1 has been clearly established in 
the liver as the key lipogenic transcription factor that regulates the expression of enzymes 
of FFA biosynthesis such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) 
(Ntambi & Kim, 2000). Previously studies demonstrated that the accumulation of TG, 
characteristic of mature adipocytes, is due an increase in lipogenic rate determined by an 
augmented expression of these enzymes (Student et al., 1980; Mackall et al., 1976). 
However, in adipocytes, the function of SREBP-1 is not clear.  
Maximal differentiation of 3T3-L1 fibroblast cells is obtained by stimulating 
preadipocytes with a mixture that includes insulin, dexamethasone (DEX), and 
isomethylbutylxanthine (IBMX) (Ntambi & Kim, 2000). Insulin is known to act through the 
insulin-like growth factor 1 (IGF-1) receptor, a protein that regulates muscle growth 
through activation of PI3/AKT pathway (Nakae et al., 2003). DEX, a synthetic 
glucocorticoid agonist, is traditionally used to stimulate the glucocorticoid receptor 
pathway and activate the transcription factor C/EBP-β. IBMX, a cAMP-phosphodiesterase 
inhibitor, is traditionally used to increase intracellular cAMP. At the nuclear level, treatment 
with IBMX results in activation of the related transcription factor C/EBP, such C/EBP-β 
and δ in turn induce transcription of C/EBP-α and PPARγ. After 5 to 7 days of stimulation, 
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adipocytes acquire a round shape and the enzymes involved in lipolysis and lipogenesis 
(Ntambi & Kim, 2000).  
 
PPARs are ligand-activated transcription factors that belong to the nuclear 
hormone receptor super-family. The name PPAR derives from the ability of the first 
identified family member, PPARα, to induce peroxisome proliferation in rodent 
hepatocytes (Christodoulides & Vidal-Puig, 2010).  PPARα is predominantly expressed in 
the liver and to a lesser extend in the heart, skeletal muscle, small intestine, and kidney 
and it has a crucial role in inducing the expression of genes involved in FFA oxidation 
(Torres et al., 2008). This factor is expressed at low levels in WAT but its expression level 
in BAT is four times higher than in the liver, being sensitive to peroxisome proliferator 
agents and fasting (Christodoulides & Vidal-Puig, 2010). In vitro, the levels of PPARα are 
similarly very low and when pharmacologically stimulated, it failed to promote 
differentiation of 3T3-L1 cells (Berger et al., 1999). However when co-expressed with 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), this 
nuclear factor induces the expression of FFA oxidation enzymes in 3T3-L1 preadipocytes 
(Vega et al., 2000). In vivo, when rats are exposure to a bezafribate (Christodoulides & 
Vidal-Puig, 2010), a PPARα activator (Peters et al., 2003), the expression of genes 
involved in FFA uptake and β-oxidation are increased. On the other hand, WAT is 
normally over-developed in animals lacking the PPARα gene and are susceptible to 
development late onset obesity despite a stable caloric intake, associated with adipocyte 
hypertrophy. In parallel, when PPARα is pharmacologically activated, there is a reduction 
of adiposity in mouse models of diet-induced and genetic obesity (Christodoulides & Vidal-
Figure 5 – Adipogenesis, Adapted from Vázquez-Vela et al. 2008 
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Puig, 2010). PPARα has also been shown to down-regulate apoliprotein C-III, a protein 
which inhibits TG hydrolysis by LPL (Lee et al., 2003). This effect of PPARα further 
contributes to the lipid-lowering effect. These results strongly indicate that reduction in 
obesity due PPARα activation is correlated with an increase in β-oxidation, which make 
this receptor a possible therapeutic target to this condition. 
 Relatively to PPARγ there are two distinct isoforms, PPARγ1 and PPARγ2.  
PPARγ1 is predominantly present in adipose tissue, but is also detected in other tissues 
as immune cells, intestine, kidney and liver. On the other hand, PPARγ2 is produced 
almost exclusively in WAT and BAT (Christodoulides & Vidal-Puig, 2010; Semple et al., 
2006). Interestingly, PPARγ2 knockout mice still have WAT, suggesting a role of PPARγ1 
to compensate the lack of PPARγ2 to sustain adipogenesis (Tontonoz et al., 1994). An 
increase in PPARγ expression is sufficient to initiate adipogenesis in vitro in 3T3-L1 
fibroblasts and in vivo (Tontonoz et al., 1994). On the other hand, adipose-specific 
deletions of the PPARγ gene leads to lipodystrophy; and dominant-negative versions of 
PPARγ, in other words, an altered gene product that acts antagonistically to the wild-type 
allele, inhibit the conversion of preadipocytes into adipocytes (Torres et al., 2008). These 
works prove the importance of this nuclear factor in adipogenesis. PPARγ also plays a 
key role in adipose tissue lipid metabolism. Its expression is increased postprandially 
(Vidal-Puig et al., 1996), and its activation leads to the upregulation of genes that 
mediate FFA uptake and storage, such as: cluster of differentiation 36 (CD36, also 
known as fatty acid translocase), LPL, fatty acid transport protein (FATP) family and 
acetyl-CoA syntethase (ACS) (Schoonjans et al., 1996; Oakes et al., 2002; Olswang et al., 
2002). PPARγ may also promote futile cycling in adipocytes between TG esterification 
and re-esterification (Guan et al., 2002a). 
Thiazolidinediones (TZDs), like rosiglitazone, are antidiabetic agents and PPARγ 
ligands that induce differentiation of preadipocytes (Zebisch et al., 2012; Berger et al., 
1996). The promotion of adipogenesis decreases insulin resistance by increasing the 
capacity to store lipids. This is due in part to PPARγ action that augments the levels of 
GLUT 4, uncoupling proteins, and adiponectin expression, all of which contributes to a 
lower risk of developing insulin resistance (Lee et al., 2003). Thus, equilibrium between 
PPARα and PPARγ activities is necessary to maintain the balance between lipid synthesis 
and oxidation. If such balance is lost, the risk of developing obesity and insulin resistance 
could be increased (Ferre, 2004). 
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1.2.3 Adipose tissue metabolism, TG/(GL+FFA) cycle and 
glyceroneogenesis 
The process of storage and mobilization of energy to supply the needs of organs 
and tissues is the responsibility of WAT. Contrarily, BAT also stores energy, but to a far 
lesser extent. It also produces heat by oxidizing FFA within the adipocytes, rather than 
supplying FFA for other cell types. Lipids, particularly fatty acids, are an exceptionally 
efficient fuel storage molecules (Vance, 2002), so is important to focus on what regulates 
the flux of FFA between tissues and organs, as illustrated in Figure 6.  
The TG/ (GL+FFA) cycle, also known as triglyceride/fatty acid cycling regulates the 
flux of FFA between tissues and organs, and is the central pathway that interlink TG and 
glucose metabolism. Most tissues are involved in fatty acid metabolism, but three are 
quantitatively more important than others: adipose tissue, skeletal muscle and liver. The 
TG/(GL+FFA) cycling is a process of fatty acid esterification (lipogenesis) with glycerol-3-
phosphate to form TG, followed by the hydrolysis (lypolysis) of TG to regenerate glycerol 
and fatty acids, which can re-enter the cycle, a process that occurs in each tissue referred 
previously (Prentki & Madiraju, 2012). It is known that in various tissues most of the FFA 
released in the cytoplasm upon lipolysis is immediately re-esterified, even at steady state 
levels of TG and FFA. Thus, this process is considered futile as 7 ATP molecules are 
consumed per each complete turn of the cycle (Prentki & Madiraju, 2012). This cycle is 
important for whole body homeostasis since lipogenesis and lipolysis generate products, 
such as glycerol, FFA and many lipid signaling molecules with influence in other organs 
and tissues, making it fundamental to have balance between these pathways (Prentki & 
Madiraju, 2012). Abnormalities associated with this cycle lead to pathological conditions 
such as insulin resistance, T2DM, non-alcoholic fatty liver disease, and even cancer 
(Prentki & Madiraju, 2012), what makes this cycle a possible therapeutic target to these 
metabolic diseases. 
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i. Adipose Tissue metabolism: Lipogenesis and Lipolysis 
 
The FFA stored in human adipose tissue reflect dietary intake (Frayn et al., 2006). 
De novo lipogenesis is the synthesis of FFA from carbohydrates or other energy sources 
acquired in the diet. Glucose is the major substrate for lipogenesis and this process 
occurs predominantly in the liver and to a lesser extent in adipose tissue. The contribution 
of adipose tissue to de novo fatty acid synthesis is less well defined in human and 
particularly in pathological situations such as diabetes and obesity (Torres et al., 2008). 
There‟s discussion about the contribution of de novo lipogenesis to adipose tissue fat 
Figure 6 - Role and interrelationship of TG/ (GL/FFA) cycle in various organs. Adapted from Prentki et 
al. 2011 
There is a continual flow of fatty acids between the three tissues described above. Dietary fat enters the 
plasma from the small intestine in the form of chylomicron-triacylglycerol. The chylomicrons are the largest of 
the lipoprotein particles and have a very fast turnover. They deliver triacylglycerol-fatty acids to tissues 
expressing the LPL. The remaining „remnant‟ particles (that have lost perhaps two-thirds of their 
triacylglycerol) are mainly taken up by the liver. This is the starting point for fatty acid metabolism in the 
tissues. Adipose tissue takes up fatty acids via the action of LPL. It releases fatty acids by the hydrolysis 
(lipolysis) of stored TG, by the action of the enzyme known as HSL and other lipases, to liberate FFA into the 
plasma. Plasma FFA circulate bound to albumin. The liver takes up fatty acids in various forms and liberates 
triacylglycerol-fatty acids as VLDL (very-low-density lipoprotein) particles. In this scenario, skeletal and heart 
muscle (and other oxidative tissues not considered here) are the only pure consumers, taking up fatty acids 
either from lipoprotein-triacylglycerol or from the plasma FFA pool and using them ultimately for oxidation. 
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stores but, at the whole-body level, it only operates significantly when carbohydrate intake 
exceeds energy requirements. However, it is clear that the key enzymes for fatty acids 
synthesis, FAS, ACC and malic enzyme are present in human adipose tissue (Torres et 
al., 2008; Large et al., 2004). Thus in adipocytes, most of FFA used for TG synthesis are 
taken from the plasma either as FFA bound to plasma albumin, or as TG incorporated in 
TG-rich lipoproteins, mainly chylomicrons (carrying diet fat) in the postprandial state and 
VLDL (secreted from the liver) in the post-absorptive state (Mead et al., 2002). FFA are 
released from lipoproteins through the hydrolysis of TG by LPL, which expression and 
activity in adipose tissue are increased in fed state (Mead et al., 2002). Then FFA 
liberated from TG can be taken up by the adipocyte and esterified to form new TG. LPL is 
synthesized within adipocytes and exported to its site of action, the luminal side of the 
capillary endothelial cells.  Contrary to the fed state, in fasting more LPL becomes inactive 
(perhaps via monomerization) (Frayth, 2003). In contrast, LPL in skeletal and cardiac 
muscle is activated during fasting (Frayn et al., 2006).  
Within the adipocyte, FFA can be taken into the mitochondrial matrix and be 
oxidized to acetyl-CoA through the fatty acid β-oxidation (Torres et al., 2008). In spite of 
LPL generating excess of FFA, adipocytes only take up a proportion depending on 
nutritional state. There is always an “overspill” of FFA to the circulation, so the insulin 
levels increase proportionally to FFA taken up by the tissue (Frayth, 2003). However in 
the postprandial state typically approximately 50% may be released as FFA, clearly 
shown by enrichment of the plasma FFA pool with dietary fatty acids soon after a meal 
(Frayn et al., 2006). These fatty acids are then available for uptake by other tissues 
including muscle and liver. It also involves stimulation of FFA esterification to make new 
TG within the adipocyte. In addition, insulin may stimulate glucose uptake and glycolysis, 
which supplies the glycerol-3-phosphate necessary for FFA esterification (Frayn et al., 
2006).  
Lipolysis is responsible by controlling the availability of FFA and TG in nonadipose 
tissues, mostly in situations of energy needs. During intracellular lipolysis, TG are broken 
down in a stepwise manner, to form three molecules of FFA and one of glycerol per unit of 
completely hydrolyzed TG (Large et al., 2004). 
First, TG stored in the lipid droplet are hydrolyzed by the enzyme adipose 
triglyceride lipase (ATGL), also known as desnutrin, releasing a diacylglycerol (DAG) and 
FFA. This enzyme is induced under fasting condition and inhibited after feeding.  After 
hydrolysis by ATGL, DAG are then hydrolyzed by the HSL, so named because of its 
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responsiveness to the hormones insulin and catecholamines, and monoglyceride lipase 
(MGL), producing FFA and glycerol. HSL is one of the major regulatory points of lipolysis. 
HSL is regulated in the long-term by transcriptional control, since mRNA abundance 
increases during starvation, and is decreased in obesity (Frayn et al., 2006). But the most 
important aspect of HSL on a day-to-day basis is its regulation by reversible 
phosphorylation, described in Figure 7 (Torres et al., 2008; Frayn et al., 2006). 
 
 
 
Figure 7 - Lipogenesis and lipolysis. Adapted from Vázquez-Vela et al., 2008.   
In the adipocyte, glucose is oxidized via glycolysis to pyruvate, which is converted to acetyl-CoA. 
Alternatively, fatty acids from lipolysis can be taken into the mitochondrial matrix and be oxidized to acetyl-
CoA through the fatty acid β-oxidation. The acetyl groups are converted into acyl-CoA, which are esterified 
in the endoplasmic reticulum to TG. These are then translocated into the lipid droplet. Under fasting 
conditions, lipolysis is activated by G-protein-coupled receptors resulting in an increase in cAMP, which 
activates PKA. PKA phosphorylates the protein perilipin located in the membrane of the adipocyte fat 
droplet. PKA also phosphorylates the HSL triggering its translocation from the cytoplasm to the lipid droplet 
and inducing the hydrolysis of diglycerides produced by the ATGL to form monoglycerides (MG). Then MG 
are hydrolyzed by MGL producing FFA and glycerol.  FFA are released to supply the energy needs of 
organism. On the other hand, in the fed state insulin suppresses HSL activity by activation of a particular 
phosphodiesterase, PDE3B, which reduces the cAMP concentration.  
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Different lipases get access to the lipid droplet when proteins that coat the lipid 
droplet, called perilipins, are phosphorylated. Usually, Perilipin A prevents lipolysis of TG 
by surrounding the lipid droplet, preventing the access of lipases. β-adrenergic stimulation 
of adipocytes leads to the activation of adenyl cyclase, which in turns increases cAMP 
concentrations. Increased cAMP levels promote the activation of cAMP dependent protein 
kinase A (PKA) and the subsequent phosphorylation of HSL and perilipin.  This leads to 
the translocation of HSL from the cytoplasm to the lipid droplet and induce neutral lipid 
hydrolysis (Torres et al., 2008; Large et al., 2004). 
During fasting, glucagon and catecholamines levels are increased, leading to the 
stimulation of lipolysis in the adipocytes by activating several lipases via PKA, leading to 
FFA mobilization from the adipocyte into circulation. FFA are then bound to albumin and 
transported to muscle, liver, heart and other tissues for its oxidation or re-esterification. β-
adrenergic receptors induce lipolysis, whereas α2-adrenergic receptors mediate 
lipogenesis. In postprandial state, high insulin concentrations inhibit lipolytic enzymes, 
decreasing lipid mobilization from adipose tissue. These effects are mediated by the 
activation of phosphodiesterase 3B that degrades cAMP, preventing the stimulation of 
several lipases, and by activating protein phosphatase-1 that causes dephosphorylation of 
HSL, in both instances reducing the rates of lipolysis (Torres et al., 2008; Large et al., 
2004). 
 
ii. Glyceroneogenesis 
 
Quantitative estimates of TG/(GL+FFA) cycle activity in human adults, newborn 
infants and in animals show that only a small portion of the FFA released as a result of 
lipolysis in the WAT are oxidized, and the majority are re-esterified to TG in various 
tissues (Reshef et al., 2003). The fraction of FFA released that is recycled back to TG 
remains relatively constant (75%). However, marked changes were verified in the rate of 
total TG/(GL+FFA) cycle during different metabolic states, including the deceleration on 
the TG/(GL+FFA) cycle in experimental models of obesity and diabetes (Reshef et al., 
2003) and acceleration of cycle by acute exercise (Schenk & Horowitz, 2007). The 
metabolic significance of the rate of triglyceride/fatty acid recycling remains to be 
determined, however it is clear that TG/(GL+FFA) recycling requires the constant 
generation of glycerol-3-phosphate for triglyceride synthesis, particularly in situations 
when cycling is increased (Figure 8) (Reshef et al., 2003).   
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In the fed state glucose is metabolized to glycerol-3-phosphate via glycolysis and 
esterified with three FFA to generate TG. This occurs both in the liver and in WAT, being 
the FFA derived both from the diet or de novo lipogenesis. FFA yield energy through β-
oxidation or can be stored as TG in adipose tissue for energy supplying at a later time. 
However, during fasting, approximately 65% of FFA are re-esterified back to TG in WAT 
(Hsieh et al., 2011). Since glucose levels are decreased during fasting, the synthesis of 
glycerol-3-phosphate from glucose is minimal. Moreover, in WAT the glycerol released 
during lipolysis cannot be phosphorylated and used for triglyceride synthesis because the 
activity of glycerol kinase in this tissue is negligible (Reshef et al., 2003). Thus, an 
alternative source of 3-glycerol phosphate during fasting other than glucose is necessary 
(Reshef et al., 2003). Some studies demonstrated that exists an alternative pathway 
called that glyceroneogenesis, which is defined as the conversion of precursors other than 
glucose or glycerol, such as pyruvate and lactate, into glycerol 3-phosphate for triglyceride 
synthesis. Thus, this pathway is exceptionally important in situations of fasting (Reshef et 
al., 2003; Reshef et al., 1970). 
Glyceroneogenesis, like gluconeogenesis, is regulated by PEPCK, a key enzyme 
which is expressed in liver, WAT and BAT and catalyzes the conversion of oxaloacetate to 
phosphoenolpyruvate, in both pathways (Reshef et al., 2003). This is supported by a 
study where the deletion of the binding site for the PEPCK (proliferator-activated receptor 
element, PPARE), abolished glyceroneogenesis in the WAT, as determined by their 
inability to synthesize glyceride-glycerol from pyruvate (Olswang et al., 2002). 
Figure 8 - The triglyceride/fatty acid cycle in mammals. Adapted from Reshef et al. 2003 
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Figure 9 - Glyceroneogenesis modulates fatty acid release during periods of fasting. Adapted from 
Beale et al. 2002 
When fuel is not available from the diet, lipolysis releases glycerol and fatty acids from triglyceride stores in fat 
cells. Fasting lowers insulin and increases intracellular cAMP, which leads to decreased glucose utilization 
and increased PEPCK production. Fatty acid release is restrained due to increased glyceroneogenesis and re-
esterification. In contrast, almost 100% of the glycerol is released because it is not phosphorylated 
significantly in adipocytes.  
Furthermore, glyceroneogenesis seems to be important in the control of triglyceride 
turnover in WAT (Reshef et al., 2003). 
 
Although insulin resistance is associated with TG mobilization from the adipose 
tissue, GLUT4-deficient mice do not exhibit TG depletion in the WAT, which may be 
explained by an enhanced activity of glyceroneogenesis (Abel et al., 2001). Moreover, 
over-expression of PEPCK in WAT has been shown to increase FFA re-esterification, 
leading to obesity, without insulin resistance (Franckhauser et al., 2002). Thus, increased 
glyceroneogenesis leads to a reduction in plasmatic FFA levels. 
BAT has a tenfold activity of PEPCK compared to the WAT, but the physiological 
significance has not been formally established (Reshef et al., 2003). Findings suggest that 
glyceroneogenesis plays a critical role in thermogenesis in BAT by controlling the rate of 
formation of glycerol-3-phosphate required for triglyceride synthesis. It has been shown 
that rats fed with high protein content diet and low on carbohydrates, exhibit increased 
glyceroneogenesis from alanine, pyruvate, and lactate in BAT, and a fourfold increase in 
PEPCK activity of, leading to increased re-esterification of FFA (Brito et al., 1999). 
Additionally, rats fed a carbohydrate free diet exhibit reduced BAT thermogenic capacity 
(Brito et al., 1992). As such, this pathway may play a critical role in determining the rate of 
FFA released from TG to BAT mitochondria for thermogenesis, since this FFA seems to 
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increase the expression of UCP-1 (Millward et al., 2010). Contrarily to WAT, BAT has an 
enhanced activity of glycerol kinase so form glycerol-3 phosphate for triglyceride synthesis 
directly from glycerol (Reshef et al., 2003). However, most of the preformed FFA are re-
esterified to TG using glycerol-3-phosphate generated via glyceroneogenesis. Thus 
glyceroneogenesis seems to play a important role in providing glycerol-3-phosphate 
required to ensure TG synthesis from dietary FFA in BAT during the fed state (Brito et al., 
1999). Finally, ablation of PEPCK in WAT and reduced expression of PEPCK in BAT 
resulted in increased plasma FFA, thus contributing to the development of insulin 
resistance (Millward et al., 2010). 
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1.3 Mitochondria  
1.3.1 General overview 
Mitochondria are essential organelles in all eukaryotic cells and are involved in 
many processes that are critical for cell survival and functioning, including metabolic 
pathways, redox control and calcium homeostasis. These organelles are also the main 
sources of reactive oxygen species (ROS) and play a key role in cell death mechanisms 
(Dalgaard & Pedersen, 2001).  
The main source of cell energy is the synthesis of ATP from ADP and inorganic 
phosphate (Pi) by oxidative phosphorylation (OXPHOS) or coupled respiration, carried out 
in the inner mitochondrial membrane. The mitochondrial respiratory chain (MRC) is 
located in the inner mitochondrial membrane, and is constituted by four multienzymatic 
complexes and two proteins responsible for electron transport, coenzyme Q (CoQ), and 
cytochrome c (Figure 9) (Coutinho et al., 2012). The protein subunits can be grouped in 
four complexes: 
 Complex I or NADH dehydrogenase; 
 Complex II or succinate dehydrogenase; 
 Complex III or cytochrome c reductase;  
 Complex IV or cytochrome c oxidase. 
The total number of polypeptides involved directly in OXPHOS is 91 when 
cytochrome c is included. Of these proteins, some are nuclear-encoded and others are 
mitochondrial-encoded in the mtDNA (Attardi & G., 1988). The mitochondrial genome 
encodes for essential proteins for the complex I, III, IV and V, but complex II subunits are 
all encoded by the nuclear genome. Because of its limited coding capacity, mtDNA relies 
on nuclear genes for structural components and biological functions (Duarte, 2012). 
Furthermore, nuclear-encoded genes also regulate mitochondrial transcription, translation, 
and mtDNA replication, thus the precise cooperation of nuclear and mtDNA expression is 
critical to regulate OXPHOS capacity in response to different physiological demands and 
disease states (Scarpulla, 2008; Peralta et al., 2011). 
 Transcription of the mitochondrial genome is under the control of a single 
transcription factor, mitochondrial transcription factor A (TFAM), which is encoded by the 
nuclear genome (Bengtsson et al., 2001). Nuclear respiratory factor (NRF)-1 and NRF-2, 
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which specifically activate numerous nuclear-encoded genes involved in mitochondrial 
respiration (Lee & Wei, 2005). Through NRF-stimulated expression of TFAM, occurs 
simultaneously the transcription of the mitochondrial genome and of nuclear-encoded 
mitochondrial genes (Patti & Corvera, 2010). The expression of mitochondrial genes is 
also controlled by additional nuclear transcription factors, including PPARα and PPARδ, 
which can induce expression of mitochondrial genes in a tissue-dependent and 
physiological context-dependent manner (Patti & Corvera, 2010). A high level of 
transcriptional coordination is required to ensure coupling of mitochondrial activity to other 
metabolic activities within the cell and to mediate appropriate parallel changes in all 
components of multiprotein complexes (Scarpulla, 2008). This coordination is 
accomplished through the action of transcriptional coactivators and corepressors (Patti & 
Corvera, 2010). The most studied coactivator of mitochondrial gene transcription is the 
PGC-1α (Knutti & Kralli, 2001), activated in cellular energy-requiring conditions such as 
cell growth, hypoxia, glucose deprivation, and exercise to activate transcription factors 
promoting mitochondrial remodeling and/or biogenesis, thus increasing cellular energetic 
capacity (Patti & Corvera, 2010). For example, PGC-1α is highly expressed in muscle, 
liver, and BAT and expression is further increased in these tissues in response to 
exercise, fasting, and cold exposure, respectively (Knutti & Kralli, 2001). PGC-1α seems 
do not be required for mitochondrial biogenesis during development, however is 
necessary for the expression of the full complement of proteins of mitochondrial OXPHOS 
and β-oxidation pathways in muscle and BAT (Sonoda et al., 2007).  
OXPHOS involves the coupling of electron transport, by means of the complexes I-
IV of the MRC, to the active pumping of protons across the inner mitochondrial 
membrane, and ATP formation by ATP synthase (Complex V). During mitochondrial 
respiration, the electron transport chain oxidizes reduced coenzymes (NADH and flavin 
adenine dinucleotide (FADH2) at Complexes I and II level, respectively) by donating 
electrons to the MRC. The movement of electrons through the MRC is driven by a redox 
potential that is found across the chain. Complexes I, III, and IV pump protons across the 
inner membrane as electrons pass down the MRC. This produces an electrochemical 
potential difference across the inner membrane, known as proton motive force, consisting 
mostly of an electrochemical gradient (membrane potential) and a chemical gradient (pH 
difference). The energy that is conserved in the proton gradient across the inner 
membrane is used by ATP synthase to synthesize ATP as protons are transported back 
from the intermembrane space into the mitochondrial matrix. The final destination of the 
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electrons is molecular oxygen (O2), which is reduced to water by complex IV, in the last 
step of the MRC.  
 
 
ROS are formed as a natural byproduct of the normal metabolism of oxygen and 
correspond to a variety of molecules and free radicals (chemical species with one 
unpaired electron) (Coutinho et al., 2012), such as superoxide anion (O2•
-) and hydrogen 
peroxide (H2O2). ROS normally exist in all aerobic cells in balance with biochemical 
antioxidants (Coutinho et al., 2012), and they are formed in response to various stimuli 
(Fridovich, 1978), since they play a role in different physiological processes (Pinkus et al., 
1996). However when this balance is broken, due an increase in ROS production, a 
decrease in antioxidants or both, oxidative stress occurs (Coutinho et al., 2012) with 
significant damage to cell structures. Mitochondria are the main sources of ROS, what 
Figure 10 – Schematic representation of coupled and uncoupled respiration. Adapted from Pati et al. 
2010 
Complex I accept fuel from the citric acid cycle in the form of NADH, which donates electrons to the chain. 
Complex II accepts electrons from FADH2 and passes to Complex III via CoQ. The electro is then passed to 
Complex IV via cytochrome c. This proton electrochemical gradient is consumed by demand pathways via 
the ATP synthase to produce ATP or by proton leak pathways, which release energy in the form of heat. 
Proton leak pathways can be mediated by UCPs or by ANT. 
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makes these organelles particularly susceptible to oxidative damage (Kirkinezos & 
Moraes, 2001).  
Mitochondria have their own ROS scavenging mechanisms that include 
superoxide dismutase, glutathione peroxidase (GSPx), glutathione dismutase and vitamin 
C (Kirkinezos & Moraes, 2001). However it has been demonstrated that they generate 
ROS at a rate higher than their scavenging capacity, resulting in the incomplete reduction 
of approximately 1–3% of the consumed oxygen (Kirkinezos & Moraes, 2001). This 
indicates that ROS production is a physiologic process that occurs in the sequence of 
aerobic metabolism (Lee & Wei, 2005). Complexes I and III produce most of ROS 
(Kirkinezos & Moraes, 2001). Specifically, is during the transfer of electrons from CoQ to 
complex III that the most significant production of superoxide anion occurs. Thus, 
inhibition of the MRC results in an increase in ROS (Turrens et al., 1985). 
The coupling of respiration to ATP synthesis is not 100% efficient, and some of the 
energy is dissipated as heat. Partial uncoupling of respiration from ATP synthesis, also 
known as proton leak, can be mediated by UCPs. Thus an increase in UCPs content 
could have severe consequences for cellular function, due to the decrease in ATP 
synthesis. On the other hand, a beneficial effect that may result from the proton "leak" is 
to prevent excessive accumulation of ROS (Teodoro, 2007). 
 
1.3.2 Uncoupling proteins 
Uncoupling proteins (1, 2, 3, 4 and 5) are a subfamily of the mitochondrial solute 
carrier family, and are located in the inner mitochondrial membrane (Azzu & Brand, 2010). 
These proteins have similarities in their structures, but different tissue expression in 
mammals. The UCP-1 was the first discovered and is mainly expressed in BAT (Coutinho 
et al., 2012). UCP-2 was mainly identified in liver (Dalgaard & Pedersen, 2001), whereas 
UCP-3 is mainly restricted to the skeletal muscle. More recently, UCP-4 and UCP-5 were 
identified, being mainly expressed in brain (Coutinho et al., 2012).   
The main function of these proteins is decrease metabolic efficiency through 
uncoupling of ATP synthesis from the MRC. However, depending on tissue, this 
uncoupling effect has different consequences, such as thermogenesis and energy 
expenditure (UCP-1), regulation of FFA metabolism (UCP-2 and UCP-3), reduction in 
 
CHAPTER I – General Introduction 
25 
 
ROS generation (UCP1-3 and UCP-5), and regulation of ATP dependent processes 
(UCP-2) (Coutinho et al., 2012). 
The uncoupling activity of UCP-1 is explained by its ability to transport protons 
across the inner mitochondrial membrane, in particular when FFA bind to the protein 
(Silva, 2006). However, the precise mechanism by which FFA regulate transport through 
UCP-1 is still unclear. There are two mechanisms proposed: the FFA protonophore (or 
flip-flop) model, and the channel (or proton buffering) model. In the flip-flop model, UCP-1 
is a carrier of fatty acid anions, which are transported by this protein from the 
mitochondrial matrix to intermembrane space. In this model, each fatty acid anion 
combines with a proton, becomes electrically neutral and flips back through the 
membrane, releasing the proton in the matrix. The channel model predicts a two domain 
structure of UCP-1 with a pore domain and a gating domain, which allows protons to pass 
through the UCP-1. In this model, fatty acid carboxyl groups are involved in the proton 
transport by providing H+ buffering capacity (Frayn et al., 2006).  
UCP-1 gene expression is increased by cold, adrenergic stimulation, β3-agonists, 
retinoid and thyroid hormones, cAMP and bile acids (Frayn et al., 2006; Watanabe et al., 
2006; Ockenga et al., 2012; Teodoro et al., 2013). Moreover, its expression is activated by 
FFA and inhibited by purine nucleotides such as, ATP and ADP (Coutinho et al., 2012).  
 
1.3.3 Mitochondrial activity in WAT and BAT 
Mitochondrial metabolism is both the origin and target of multiple nutrient signals that 
coordinate integrated physiological responses to maintain cellular insulin sensitivity 
(Kusminski & Scherer, 2012) and play key roles in the metabolism of adipose tissue, both 
in WAT and BAT (Figure 11).  WAT has less mitochondrial content when compared to 
BAT. This tissue interprets nutritional and hormonal signals in its microenvironment and 
then coordinates its mitochondrial response, either to oxidize incoming FFA and 
carbohydrate fuels through the tricarboxylic acid (TCA) cycle and the respiratory chain, or 
to store these fuels in the form TG until their release in situations of energy requirements 
(Kusminski & Scherer, 2012). Mitochondria play an important role in lipogenesis by 
providing acetyl-CoA for FFA synthesis, before their esterification into TG. Furthermore, 
mitochondria provide a key intermediary for the synthesis of TG, glycerol-3-phosphate 
through the glyceroneogenic pathway. This organelle is also involved in the regulation of 
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lipolysis with FFA resulting from lipolysis being oxidized by β-oxidation pathway in the 
mitochondrial matrix. This process of removal of FFA within white adipocytes by fatty acid-
induced mitochondrial β-oxidation would protect the organism against FFA leakage out of 
adipocytes, thereby preventing lipotoxicity-induced insulin resistance in other organs such 
as liver, muscle or beta cells (Medina-gómez, 2012). Furthermore, the synchronized 
initiation of adipogenic process and mitochondrial biogenesis indicates that mitochondria 
play a pertinent role in the differentiation and maturation of adipocytes (De Pauw et al., 
2009). 
On the other hand, BAT is known to generate heat through dissipation of chemical 
energy, a process known as thermogenesis. When animals are subjected to cold stimulus 
or ingest surplus energy, their sympathetic nervous is stimulated and catecholamines are 
released. Catecholamines activate adenyl cyclase, which is able to convert ATP to cAMP. 
In addition, cAMP also activates lipases to release FFA from TG (Silva, 2006). These FFA 
act as fuel for the thermogenic process and are endogenous activators of UCP-1 (Silva, 
2006). 
Since the discovery of UCP-1 in BAT, and its capacity to increase energy 
expenditure through thermogenesis (Nicholls, 1983), many studies have focused its 
attention in this protein as a target in obesity and related disorders (Enerbäck et al., 1997; 
Bradford et al., 1993; Floryk et al., 1999; Kopecky et al., 1995; Silva, 2006; Matthias et al., 
2000). By discharging the proton gradient that is produced across the inner mitochondrial 
membrane during substrate oxidation without producing ATP, BAT exhibits higher rates of 
oxidation, particularly fatty acids. In this way, animals with active BAT can partition excess 
energy intake toward oxidation and thus away from storage as body fat (Schoeller, 2001). 
In humans, UCP-1 expression in the intraperitoneal fat of obese subjects is 50% 
lower than in normal weight subjects, in spite of the fact that the amount of BAT 
interspersed in WAT depots in adult individuals is relatively low (Frayn et al., 2006). Other 
works have shown that UCP-1 may be ectopically induced to be expressed in WAT, and 
thus could be exploited to increase the capacity to oxidize fatty acids in white adipocytes, 
and thereby regulate body fat mass. Induction of UCP-1 expression in white adipocytes 
has been achieved in vitro (Tiraby et al., 2003) and in vivo (Kopecky et al., 1995). In vivo, 
the fat-specific ap2 promoter has been used to construct transgenic mice that express 
UCP-1 in both BAT and WAT. These mice were resistant to genetic obesity and possess 
WAT cells with an increased mitochondrial content (Kopecky et al., 1995). In vitro, 
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expression of PGC-1α in white adipocytes not only induced UCP-1 expression, but also 
stimulated mitochondrial biogenesis and the expression of mitochondrial enzymes of the 
respiratory chain and fatty acid oxidation (Tiraby et al., 2003). Together, these findings 
suggested that UCP-1 could be an integral component of cellular energy control but the 
specific role of UCP-1 remains to be fully elucidated.  
 
. 
 
1.3.4 Mitochondrial dysfunction in obesity and T2DM 
Obesity and T2DM are associated with an increase in ROS production and 
consequently mitochondrial damage in various organs, such as adipose tissue, liver and 
muscle (Patti & Corvera, 2010; Kusminski & Scherer, 2012; Alfadda & Sallam, 2012), 
which results in oxidative damage and irreversible loss of mitochondrial function (Teodoro, 
2007). Impaired mitochondrial function is associated with insulin resistance and secretion 
of proinflammatory adipokines (Kusminski & Scherer, 2012). 
In the adipose tissue, reduction in mitochondrial mass is usually associated with 
obesity and T2DM (Kusminski & Scherer, 2012). This is related to a reduction in both FFA 
β-oxidation and OXPHOS rates, leading to an increase of cytosolic FFA levels that alter 
glucose uptake and consequently lead to insulin resistance (Medina-gómez, 2012; 
Figure 11  - Mitochondrial functions in WAT and BAT. Adapted from Medina-Gómez et al., 
2012 
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Kusminski & Scherer, 2012). In fact, mitochondrial content in white adipocytes derived 
from epididymal fat-pads of ob/ob mice arise approximately 50% lower than in lean control 
mice (Wilson-fritch et al., 2004). At a cellular level, the lost of function of mitochondria 
leads to glucose and lipid management disorders, which in turn result in lipid accumulation 
in non-adipose tissues, such as liver and muscle (Listenberger et al., 2003). This 
lipotoxicity process alters the metabolism of these tissues, contributing to development of 
insulin resistance.  
Studies have also revealed that several mitochondrial genes crucial for mitochondria 
function and replication, including PGC-1α, are downregulated in obese, high-fat diet-fed, 
insulin-resistant mice, and in db/db mice. This suggests that mitochondrial biogenesis is 
highly compromised in WAT of obese insulin-resistant mouse models (Keller & Attie, 
2010). Furthermore, an excessive caloric intake increases ROS production and causes 
deleterious effects in cells. ROS reduce oxygen consumption in adipocytes (Wang et al., 
2010) and have been demonstrated to inhibit preadipocyte 3T3-L1 cell line model‟s 
proliferation (Carrière et al., 2003) and differentiation (Carrière et al., 2004). In these 
conditions, the expression of PPARγ and adiponectin was down-regulated and the 
expression of proinflammatory adipokines was up-regulated. Furthermore, increased ROS 
production has been found in mouse models of obesity, with increased expression of 
NADPH oxidase and inhibition of antioxidant enzymes such as superoxide dismutase, 
glutathione peroxidase and catalase (Furukawa et al., 2004). Likewise, increased levels of 
TNF-α decrease endothelial nitric oxide synthase expression and mitochondrial 
biogenesis, in adipose tissue from obese mice (Valerio et al., 2006).  
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1.4 Therapeutic interventions to obesity and associated disorders 
 
1.4.1 Current therapies 
Therapeutic strategies to improve adipocyte mitochondrial function could lead to 
improvements on whole-body insulin sensitivity. Currently there are some therapeutic 
strategies that aim to improve adipose tissue mitochondrial function and effectively treat 
obesity-induced T2DM. One of these strategies is a pharmacological intervention, such as 
the use of TZDs that increase mitochondrial mass (Kusminski & Scherer, 2012). As 
previously described TZDs are antidiabetic drugs since they increase the insulin sensitivity 
of WAT and skeletal muscle, in part because they are PPARγ agonists (Zebisch et al., 
2012; Berger et al., 1996). Besides promoting adipocyte differentiation these drugs lead to 
an increase in mitochondrial biogenesis (Wilson-fritch et al., 2004).  
In addition to TZDs, the process of „browning‟ the WAT is an emerging and promising 
therapeutic strategy against obesity. Browning is the process by which brown-like 
adipocytes appear at anatomical sites characteristic of WAT. This strategy focuses in 
inducing a switch of WAT to a BAT-like phenotype through, amongst other, enhancement 
of mitochondrial biogenesis (Kusminski & Scherer, 2012). Mitochondrial biogenesis is 
driven in part through the activity of PGC-1α, which serves as coactivator of nuclear 
transcription factors, such PPARγ and PPARα, that are involved in the induction of lipid 
accumulation and β-oxidation, respectively (Kusminski & Scherer, 2012). This therapeutic 
manipulation aims to promote weight loss and insulin sensitivity, while preventing lipid 
accumulation through UCP-1 mediated mitochondrial thermogenic uncoupling. 
Other therapeutic strategy was enhancing adipocyte mitochondrial function through 
the use of chemical uncouplers to dissipate energy as heat, reducing ATP synthesis by 
increasing proton leakage. Indeed, a study in 1930‟s used the chemical uncoupler 2,4-
dinitrophenol (DNP) as a dietary drug and this created massive weight losses, as much as 
3 kg per week (Harper et al., 2001). However, such uncoupling effects must be tightly 
controlled because a hypermetabolic state can lead to fatal uncontrolled thermogenesis in 
many tissues, including WAT, leading to chronically elevated body-temperatures (Hsiao et 
al., 2005). Thus, the use of uncouplers was discontinued, but the rationale behind it 
stands.  
Aerobic endurance exercise is another strategy that improves whole-body glucose 
homeostasis by stimulating skeletal muscle mitochondrial respiratory activity and 
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mitochondrial biogenesis, by increasing gene expression levels of PGC-1α and TFAM. In 
addition to exercise, caloric restriction can also induce mitochondrial biogenesis, oxygen 
consumption and ATP synthesis; such effects have additional ROS-reducing benefits 
(Kusminski & Scherer, 2012).   
All strategies described have the same aim that it is stimulate fuel oxidation in WAT 
and shift the balance toward less fuel storage and more substrates consumption. Thus, 
taking into account what was described in the previous two sections, if one could increase 
both the TG/(GL+FFA) cycle activity while removing one of its end products towards 
oxidation, it is possible that further cycling will occur and thus lead to decreased obesity. 
In other words, stimulate glyceroneogenesis pathway to increase glycerol-3-phosphate 
production and consequently augment FFA uptake; and at the same time, increase FFA 
β-oxidation.  However, to increase the oxidation of substrates, the stimulation of futile 
cycle and mitochondrial function must occur in parallel. Currently there is no known 
strategy to the coupling of these processes. 
 
1.4.2 Bile acids  
i.  Metabolism  
Bile acids (BA), together with cholesterol, phospholipids and bilirubin, are the main 
constituents of bile (Thomas et al., 2008). They are synthesized from cholesterol in the 
liver and secreted from hepatocytes into the bile canalicular system and subsequently 
stored in the gall bladder. After meals, bile flows into the duodenum, where it contributes 
to the solubilization and digestion of fats and lipid-soluble nutrients. Of the BA pool, 95% 
are then absorbed by passive diffusion and active transport from the terminal ileum and 
transported back to the liver, in the so-called enterohepatic circulation. The remaining 5% 
of the BA pool is lost with the feces and replaced by hepatic de novo synthesis (Staels & 
Fonseca, 2009). After a meal, BA levels increase in the intestine and liver, and also in the 
systemic circulation (from ~5 µM to ~15 µM in humans), which might exert systemic 
effects. Serum bile-acid levels therefore vary during the day following a rhythm that is 
dictated by the ingestion of meals. Taking into account these observations, systemic bile 
acids inform the peripheral tissues that a meal has been ingested and that energy will 
become available (Thomas et al., 2008).  
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The immediate products of the bile acid synthetic pathways are referred to as 
primary BA. Cholic acid (CA) and chenodeoxycholic acid (CDCA) are the primary bile 
acids formed in humans. The action of intestinal bacterial flora on primary BA results in 
the formation of secondary bile acid species: deoxycholic (DCA) and lithocholic acids 
(LCA), derived from CA and CDCA, respectively. Due to previously discussed recycling of 
BA, these species are by far the most abundant in humans. The synthesis of BA involves 
two distinct pathways, classic (neutral) and alternative (acidic) pathways, as illustrated in 
Figure 11. The first is characterized by hydroxylation of cholesterol, catalyzed by the 
cytochrome P450 enzyme cholesterol 7α-hydroxylase (CYP7A1), in the first step. The 
activity of CYP7A1 is subject to complex modes of control. This pathway is the main 
source of cholesterol-derived BA synthesis. On the other hand, BA synthesis can also 
occur by the alternative pathway, which is governed by the enzyme CYP27A1 and 
converts oxysterols to BA. Unlike CYP7A1, CYP27A1 isn‟t regulated by BA but it is 
estimated that only 6% of bile acid synthesis occurs via this pathway (Lefebvre et al., 
2009). The subsequent conversion of bile acid intermediates from either the classical or 
alternative pathways to CA or CDCA is governed by microsomal sterol 12α-hydroxylase 
(CYP8B1). The interaction of primary BA with this enzyme determines the amount of CA 
versus CDCA formed. Hydroxylation via CYP8B1 results in the formation of the more 
hydrophilic CA molecule. Thus, the CA/CDCA ratio determines the general hydrophobicity 
of the BA pool. Since BA are powerful detergents, at high concentrations they might be 
cytotoxic. For this reason, BA exert negative feedback on their own synthesis (Lefebvre et 
al., 2009).  
 
Apart from their role in dietary lipid and cholesterol homeostasis, a growing body of 
evidence suggests that BA also act as a signaling molecules and are involved in the 
regulation of energy expenditure (Ockenga et al., 2012; Watanabe et al., 2006). Moreover, 
BA metabolism seems to be altered in T2DM patients and the manipulation of the BA pool 
Figure 12 - Bile acids biosynthetic pathways. Adapted from Fiorucci et al. 2009 
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can improve glucose metabolism, insulin sensitivity, energy homeostasis as well as lipid 
metabolism in such patients (Prawitt et al., 2011). Although BA are involved in the 
activation of many signaling pathways, two major BA-regulated signaling mechanisms 
have been receiving the most attention in the scientific literature, the G-protein-coupled 
membrane receptor (TGR5) and the orphan nuclear receptor, farnesoid X receptor (FXR) 
(Thomas et al., 2008). 
ii. Bile acids as regulatory molecules and their clinical significance 
As described before, the most studied BA receptors are the nuclear receptor FXR 
and membrane receptor TGR5 which are involved in lipid and glucose metabolism (Porez 
et al., 2012), summarized in Figure 13. FXR is a member of the orphan nuclear hormone 
receptor superfamily and is mainly expressed in liver and intestine, the main sites of bile 
acid metabolism, but also in adipose tissue, pancreas and adrenals glands (Porez et al., 
2012). CDCA is the most effective natural activator of FXR, effective at a concentration of 
10μM, while LCA, DCA and CA bind with lower affinity and specificity(Prawitt et al., 2011; 
Fiorucci et al., 2009).  Upon ligand-binding, FXR acts either as a homodimer or forms a 
heterodimer with RXR (retinoid X receptor) to subsequently activate or repress the 
expression of genes that contain a specific FXR response element in their promoter 
(Fiorucci et al., 2009). Furthermore, numerous FXR functions are mediated  by  the  
induction  of  Short Heterodimer  Protein (SHP)  which  in  turn represses target genes in 
bile acid, lipid and glucose metabolism. FXR was originally characterized for its ability to 
regulate genes involved in BA synthesis, detoxification and excretion. However, nowadays 
is known that FXR is involved in glucose metabolism, insulin sensitivity, energy and lipid 
metabolism (Fiorucci et al., 2009). 
Several studies have tried to understand the role of FXR. In the 1970‟s, it was 
observed that CDCA administration to gallstone-suffering patients solubilizes cholesterol-
rich stones and decreased blood TG levels (Iser et al., 1975). This effect has now been 
linked to FXR activation (Kast et al., 2001). Also, this nuclear factor seems to be 
responsible for changes in transcription of several genes involved in FA and TG synthesis, 
such as FAS and ACC, and lipoprotein metabolism (Teodoro et al., 2011). The 
administration of synthetic FXR agonists (as GW4064, 6a-ethyl-chenodeoxycholic acid (6-
ECDCA) and WAY-362450) to rats or mice reduces plasma TG and cholesterol levels 
(Fiorucci et al., 2009). Furthermore, FXR deficiency results in an increased plasmatic level 
of TG, cholesterol, high-density lipoprotein (HDL) and FFA. By using GW4064, it is 
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possible to inhibit hepatic TG synthesis, in a mechanism that involves alterations of 
SREBP1c expression levels with the concomitant downstream effects. However, FXR 
might impact TG metabolism by other mechanisms, including induction of PPARα and 
PGC-1α (Fiorucci et al., 2009). FXR might also involved in the modulation of 
gluconeogenesis in liver, muscle and adipose tissue, since administration of CDCA 
decreases gluconeogenesis in fed mice by reducing the expression and/or activity of 
PEPCK, glucose-6-phosphatase and fructose-1,6-biphosphatase (Yamagata et al., 2004). 
Moreover, loss of FXR disrupts normal glucose homeostasis and leads to insulin 
resistance (Ma et al., 2006). Indeed, FXR activation, trough administration of CDCA, was 
shown to increase the insulin-mediated uptake of glucose (Rizzo et al., 2006).   
Due to the importance that FXR seems to have to lipid and glucose metabolism 
and insulin sensitivity, this nuclear factor appears to be also involved in some pathologies 
like obesity, T2DM and non-alcoholic fatty liver (NASH). Pharmacological studies in obese 
fa/fa Zucker rats, a model of NASH and T2DM, showed that administration during 12 
weeks of 6-ECDCA reduced body weight gain, hyperglycemia and hyperlipidemia, hepatic 
lipid content and serum insulin, glucose, FFA, triglyceride and cholesterol levels, and 
ameliorated liver histology (Cipriani et al., 2010). Moreover, the expression of FXR itself is 
decreased in rat models of type 1 and T2DM (Duran-Sandoval et al., 2004). Even though 
adipose tissue is not a tissue classically involved in BA metabolism, it expresses FXR. In 
FXR-deficient mice, adipose tissue mass and adipocyte size are reduced, indicating a role 
for FXR in adipocyte biology (Cariou et al., 2006)  and basal lipolysis is increased 
whereas lipogenesis is reduced (Abdelkarim et al., 2010). Indeed, FXR controls adipocyte 
differentiation and function by promoting the expression of several genes, including 
C/EBPα, PPARγ and SREBP1c (Teodoro et al., 2011). Furthermore, as described 
previously obesity is characterized for a state of inflammation where adiponectin 
expression is decreased, whereas TNF-α, IL-6, leptin, resistin and RBP-4 are increased. 
FXR agonism leads to an increase in adiponectin expression and a repression in TNF-α. 
Thus, FXR seems to have a important role in control of adipokines release, both in normal 
conditions as in situations of obesity (Teodoro et al., 2011).  
FXR is also involved in the regulation of PPARα and PPARγ. PPARα, as described 
in the previous section, is a key regulator of lipid metabolism by positively regulating FFA 
uptake and β-oxidation. Indeed, activation of PPARα leads an increase in β-oxidation, 
lipolysis, energy uncoupling and expenditure, while decreases lipogenesis, TG secretion 
and adiposity (Teodoro et al., 2011). However, future works are required, since exist some 
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controversy between studies exist. If on the one hand, there is evidence suggesting that 
PPARα might activate FXR expression (Zhang et al., 2004), on the other in C57BL/6J and 
KK-Ay mice treated with CA, there was no increase in expression of genes involved in β-
oxidation; in fact, expression of some genes decreased in C57BL/6J mice (Watanabe et 
al., 2004). PPARγ, as also previously discussed, is a key regulator in lipid metabolism and 
it was recently reported that FXR is necessary for full PPARγ activation, and some of the 
beneficial effects of FXR activation on adipose tissue are mediated by PPARγ 
(Abdelkarim et al., 2010). 
 TGR5 is a member of the rhodopsin-like superfamily of G protein coupled 
receptors that transduces signals through Gs protein (α–βγ subunits), and was recently 
identified as a BA receptor (Fiorucci et al., 2009). TGR5 is mainly expressed in the gall 
bladder, ileum, colon, BAT and WAT, and to a lesser extent in skeletal muscle, liver and 
immune cells; and is activated by nanomolar concentrations of LCA and TLCA and 
micromolar concentrations of CA, DCA and CDCA (Prawitt et al., 2011). After ligand 
binding to plasma membrane-bound TGR5, the receptor is internalized, the Gαs subunit 
released and adenyl cyclase activated. The accumulation of cAMP leads to activation of 
PKA or the transcription factor CREB (cAMP response element binding protein), 
mediating BA functions in energy and glucose homeostasis (Prawitt et al., 2011). 
There are some evidences that TGR5 is involved in the regulation of glucose 
homeostasis. One study observed that activation of TGR5 stimulates the secretion of 
glucagon-like peptide (GLP1). GLP1 belongs to the family of incretins, a group of 
insulinotropic gastrointestinal hormones secreted by intestinal entero-endocrine cells into 
the bloodstream within minutes after eating. The main physiological role of incretins is to 
regulate insulin secretion in response to meals. The authors demonstrated that LCA and 
DCA TGR5-dependently induced intracellular cAMP concentrations and GLP1 secretion 
from intestinal L-cells (Katsuma et al., 2005). In a second study, the TGR5 agonist 
oleanolic acid reduced obesity and improved insulin resistance in mice upon high-fat diet-
feeding (Strehle et al., 2007). Further support comes from a study that show that glucose 
tolerance reduced by TGR5-deficiency and improved by TGR5 overexpression in high-fat 
diet-fed mice via increased GLP1 and insulin secretion (Thomas et al., 2010).  
TGR5 also seems to play a role in energy homeostasis (Watanabe et al., 2006; 
Ockenga et al., 2012). Watanabe and colleagues have shown that BA increase energy 
expenditure by acting in thermogenically competent tissues, such as BAT in mice and 
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muscle in humans (Watanabe et al., 2006). This effect has been linked to the prevention 
of diet-induced obesity and insulin resistance in mice fed a high-fat diet. The authors 
hypothesize that induction of energy expenditure by CA requires a TGR5-dependent 
increase in intracellular cAMP and induction of Dio2, a gene whose protein product is the 
enzyme 2-iodothyronine deiodinase or D2. 
 
 
BA induce D2 expression in thermogenically relevant tissues described before, 
because only these tissues co-express both TGR5 and D2. D2 then converts locally 
available thyroxine (T4) to tri-iodothyronine (T3), resulting in increased energy expenditure 
without leading to changes in circulating thyroid hormone levels. In addition to D2, several 
genes involved in the regulation of energy expenditure were increased in brown adipose 
tissue after BA treatment, such as PPARα, PGC-1α and UCP-1 (Watanabe et al., 2006). 
The stimulation of energy expenditure by bile acid is observed only when mice are fed a 
Figure 13 - Role of FXR and TGR-5 in adipose tissue. 
Agonism of FXR leads to a repression of TNF-α, an increase in adiponectin, PPARγ, PPARα expression and 
adipocyte differentiation; which in turn leads to an improvement in insulin sensitivity, an increase in β-oxidation 
and lipolysis and a decrease in lipogenesis. On the other hand, agonism of TGR-5 increases expression of 
PPARα, PGC-1α and UCP-1 leading to an augment in β-oxidation, energy uncoupling and oxidative 
phosphorylation. 
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high-fat diet and not in D2 knockout mice (Watanabe et al., 2006). Exactly how T3, 
mediates an increase in energy expenditure remains to be clarified. One potential 
mechanism is T3-mediated induction of UCP-1 expression, leading to dissipation of the 
proton gradient generated by the electron transport chain, resulting in a decrease in ATP 
synthesis (Watanabe et al., 2006). Ockenga and colleagues have shown also there is a 
consistent relation between administration of BA and energy expenditure in humans, 
through thyroid function and activation of TGR-5 (Ockenga et al., 2012). However, even 
though that this evidences are an attractive concept, the current explanation for the 
mechanism by which this happens is being contested. Neither the overexpression nor the 
absence of TGR5 in mice leads to a difference in body weight and the susceptibility to 
diet-induced obesity is gender-specific (Maruyama et al., 2006). Taking into account these 
findings, BA seems to have a high potential to act as signaling molecules in the 
improvement of glucose metabolism, insulin sensitivity, energy homeostasis and lipid 
metabolism. In addition to studies that demonstrated that BA seems to have anti-obesity 
effects (Watanabe et al., 2006; Ockenga et al., 2012), a recent study revealed that CDCA, 
could in fact reduce obesity and associated metabolic disorders (Teodoro et al., 2013). 
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1.5 Aims / Objectives 
Nowadays, obesity is considered a major worldwide concern since associated to 
this condition is other co-morbidities that contribute to reduce life expectancy. The failure 
of current therapies towards a significant and stable reduction in global obesity and 
diabetes leads to further investigation on novel therapeutic targets for these conditions.    
One of such targets is the “acceleration” triglyceride/glycerol-free fatty acid 
(TG/(GL+FFA)) cycle. If one could increase both the TG/(GL+FFA) cycle activity while 
removing one of its end-products towards oxidation, it is possible that further cycling will 
occur and thus lead to decreased obesity. To further this idea, the deceleration and 
alterations on the TG/(GL+FFA) cycle have been demonstrated in experimental models of 
obesity and diabetes. Thus, since the current explanation for the mechanism by which 
CDCA induces energy expenditure is controversial, one possible explanation is that 
CDCA could affect TG/(GL+FFA) cycle activity. CDCA activates both PPARγ and PPARα, 
two transcription factors that are involved in the transcription of key metabolic genes, like 
the some enzymes of the TG/(GL+FFA) cycle and of mitochondrial oxidative capacity; and 
of genes involved in FFA oxidation, respectively. 
Thus, this work will focus on evaluating the metabolic alterations to the 
TG/(GL+FFA) induced by CDCA. Specifically, we will address if CDCA supplementation 
alters the TG/(GL+FFA) cycle activity, if this is related to improved metabolic status and if 
mitochondrial alterations are involved. 
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2. Methods and Materials 
2.1 Materials 
Except when noted, all compounds were purchased from Sigma-Aldrich (St. Louis, MO). 
All reagents and chemicals used in this work were of the highest grade of purity 
commercially available.  
2.2  Studies with cellular culture of 3T3-L1 cells 
2.2.1.1 Cell culture 
 The fibroblast cell line 3T3-L1 was originally developed by clonal expansion from 
murine Swiss 3T3 cells. It has a high potential to differentiate from fibroblasts to 
adipocytes, for this cell line has been widely used in studies about adipogenesis, 
biochemistry of adipocytes and metabolism (Zebisch et al., 2012). 
 3T3-L1 cells were obtained from American Type Culture Collection (ATCC). All 
cells care and maintenance was done according to the protocol recommended by ATCC. 
The cells were grown in 75-cm2 culture flasks (Sarstedt AG & Co., Germany) at 37°C in a 
humidified atmosphere with 5% CO2 and maintained in maintenance medium consisting of 
Dulbecco‟s Modified Eagle Medium (DMEM), supplemented with 25 mM Glucose, 18 mM 
Sodium Bicarbonate, 2 mM L-glutamine, 1 mM Sodium pyruvate, Antibiotic/antimycotic 
1% (Invitrogen, Carlsbad, CA) and 10% of newborn calf serum (NCS) (Invitrogen). Cells 
were passaged or harvested for experiments when reaching 70-80% of confluence, by 
detachment with 0,05% trypsin and 0,5 mM EDTA (Invitrogen). Reseeding was took into 
consideration ATCC‟s recommendations for this specific cell line, two times per week, with 
a dilution factor of between 1:5 and 1:8 of original cell content.  Cells were counted with 
an automated cell counter (Bio-Rad TC10TM Automated Cell Counter, Bio-Rad, Hercules, 
CA) and seeded in 12-well plates (Orange Scientific, Braine-l‟Alleud, Belgium) at a density 
of 5 x 104 cells/well. This cell count method uses the trypan blue exclusion method, which 
is based on membrane integrity determined by the uptake of the dye to which the cell is 
normally impermeable. Thus viable cells will exclude trypan blue dye, while dead cells will 
have blue cytoplasm and dark nuclei.  
At this point, was let cells grown during 48h hours and when cells reached 
confluence the medium was replaced for the first time. After 48h, cell differentiation was 
induced by changing the medium to DMEM containing glicose 25 mM, 18 mM Sodium 
 
CHAPTER II – Methods and Materials 
42 
 
Bicarbonate,  2mM L-glutamine, 1mM Sodium pyruvate, Antibiotic/antimycotic 1%, 10% of 
fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), 0,5 mM IBMX, 0,25 μM DEX, 1μg/ml 
insulin (Invitrogen, Carlsbad, CA) and 2 μM rosiglitazone ( Cayman Chemical Company, 
Michigan, USA). According to ATCC recommendations differentiation medium doesn‟t 
contain rosiglitazone, however when trying to differentiate the cells to adipocytes using 
conventional protocol, we encountered the following problem: the differentiation efficiency 
was low and declined rapidly with the passage number. So the protocol differentiation 
used in this work was based in protocol defined by Zebish and coworkers (Zebisch et al., 
2012), that concluded that supplementation of rosiglitazone in differentiation medium 
leads to a complete and efficiency differentiation of 3T3-L1.  After 48 h, the medium was 
changed to DMEM-similar to. On day 7, the medium was changed to Differentiation 
medium 2, equal to Differentiation medium 1 minus IBMX and DEX. This medium was 
refreshed every 48 hours until cells were totally differentiated, usually between 7 and 10 
days, as evidenced by observation of lipid droplet formation (Figure 12). 
 
 
When cells were totally differentiated the treatment with CDCA was initiated. The 
cultures were maintained in the Differentiation medium 2 supplemented with CDCA, 
according to figure 13, for 96 h after which the assays were performed. 
 
 
 
Figure 14 – Optical microscopy photography of differentiated 3T3-L1 cells, day 8. 
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2.2.2 Oil red O Staining  
 To document lipid accumulation, Oil Red O staining was performed according to 
the method described by González and coworkers (González et al., 2012). This technique 
detects neutral lipids and lipid droplets, allowing an easy estimation of cells lipid content 
and distribution (Mehlem et al., 2013). Firstly, an Oil Red O stock solution was prepared 
by stirring 0.5% Oil Red O in isopropanol overnight. The solution was filtered through a 
0.2-μm filter and stored at 4°C. Then fresh Oil Red O working solutions were prepared by 
mixing stock solution with distilled water (6:4), followed by incubation for 20 minutes and 
further filtration (Zebisch et al., 2012). At the end of the experiment, 3T3-L1 differentiated 
cells were washed with phosphate-buffered saline (PBS) (pH 7.2) twice, fixed in 10% (v/v) 
p-formaldehyde for 30 minutes, rinsed twice in PBS and once in distilled water, and then, 
stained with Oil Red O for 1 hour, in constant horizontal agitation. After staining, the wells 
were washed three times with distilled water. Finally isopropyl alcohol was added to he 
weels, extracting the total lipid content, which was measured in a 96 multiwell plate using 
colorimetric assay in a Victor3 1420 series plate reader (Perkin-Elmer, Waltham, MA), at 
490 nm. To obtain an estimate of lipid content/viable cells, the relative fluorescence units 
from the Oil Red data were normalized using the absorbance values from the viability data 
measured by the Sulforhodamine B method, described in section 2.2.5. 
Figure 15 - Scheme of CDCA treatment in 12- well plate.  
The first four wells were maintained with FBS and CDCA vehicle, ethanol (ETOH) and were considered the 
controls; the next four wells were treated with 10 μM CDCA and the last four with 50 μM CDCA.  
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2.2.3 Mitochondrial membrane potential evaluation 
To evaluate mitochondrial membrane potential (Δψ), after 96 h of CDCA treatment 
the medium was aspirated and the cells were loaded with 6,6 μM tetramethylrhodamine 
methyl ester (TMRM) in dimethyl sulfoxide (DMSO) in 1 mL of DMEM without NCS or FBS 
at 37 ºC, in a humidified atmosphere with 5% CO2 and in the dark, during 30 minutes. 
TMRM is a membrane-permeable cationic fluorophore that accumulates 
electrophoretically in mitochondria in proportion to their Δψ. After this incubation period, 
the medium with TMRM was removed and was added 1 mL the same medium but without 
the fluorescent dye.  Fluorescence was measured using excitation and emission 
wavelengths of 485 and 590 nm respectively, at 37 ºC in the same plate reader as 
described before. Since TMRM increases or decreases fluorescence intensity 
proportionally to a stimulus that increases or decreases the levels of Δψ, it‟s imperative to 
measure fluorescence intensity of this probe at the baseline level and after the application 
of a specific stimulus. Thus, after 5 minutes of recording basal fluorescence, cells were 
incubated with 1mM Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), a 
mitochondrial uncoupler. Δψ was estimated taking into account the complete 
depolarization caused by FCCP (Rolo et al., 2003),(Joshi & Bakowska, 2011). To 
normalize, the relative fluorescence units from the mitochondrial membrane potential data 
were divided by absorbance values from the viability data measured by the 
Sulforhodamine B method, described in section 2.2.5. 
2.2.4 Mitochondrial ROS generation 
 ROS generation was fluorometrically determined using 2‟,7‟–
dichlorofluorescein diacetate (DCFDA), a fluorogenic dye that measures hydroxyl, peroxyl 
and other ROS species within the cell. After diffusion in to the cell, DCFDA is deacetylated 
by cellular esterases to a non-fluorescent compound, which is later oxidized by ROS into 
2‟, 7‟ –dichlorofluorescin (DCF). DCF is a highly fluorescent compound which can be 
detected by fluorescence spectroscopy with maximum excitation and emission spectra of 
488 nm and 515 nm, respectively (Joshi & Bakowska, 2011). After the 96 h treatment, the 
medium was aspirated and the cells were loaded with 50 mM DCFDA in DMSO in 1 mL of 
DMEM without NCS or FBS at 37 ºC, in a humidified atmosphere with 5% CO2 and in the 
dark, during 30 minutes. After this incubation period, the medium with DCFDA was 
removed and was added 1 mL the same medium but without the fluorescent dye.  
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Fluorescence was measured using excitation and emission wavelengths described above, 
at 37 ºC and in the same plate reader as before. As described in mitochondrial membrane 
potential evaluation, in this assay it is necessary the application of a specific stimulus after 
reading the basal fluorescence. Thus, after 5 minutes of recording basal fluorescence, 
cells were incubated with 1mM Antimycin A, a well-known specific inhibitor of 
mitochondrial respiratory chain Complex III which induces inhibition of cell respiration, 
thus inducing heightened ROS generation (Carrière et al., 2009). Mitochondrial ROS 
generation was estimated taking into account the ROS overproduction caused by 
Antimycin A. To normalize, the relative fluorescence units from the mitochondrial ROS 
data were divided by absorbance values from the viability data measured by the 
Sulforhodamine B method, described in section 2.2.5. 
2.2.5 Sulforhodamine B colorimetric assay 
The sulforhodamine B (SRB) assay is used for cell density determination, based 
on cellular protein content. The SRB assay provides a colorimetric end point that is 
nondestructive, indefinitely stable, and visible to the naked eye. SRB strongly absorbs 
light excitation at 488 nm, providing a sensitive measure of drug-induced cytotoxicity 
(Vichai & Kirtikara, 2006).  
First, cells were briefly washed with PBS and fixed in 10% (v/v) p-formaldehyde for 
30 minutes. After fixation the wells were rinsed twice in PBS and once in distilled water, 
and air-dried. Then SRB solution (0,5% in 1 % acetic acid) was added to each well in 
sufficient amount to cover the culture surface area, about 500 μL. The plate was 
incubated at room temperature and in agitation, for 30 minutes. After the incubation 
period, unbound dye was removed by four washes with 1% acetic acid before air-drying 
one more time. Finally, the protein-bound dye was solubilized in 10 mM Tris (pH 10) using 
a volume equal to the original volume of culture medium (1 mL), during 5 minutes at room 
temperature and in agitation. The absorbance was read at 540 nm and blank background 
optical density was measured in wells incubated with growth medium without cells.  
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2.2.6 Cell viability assay – LDH 
Cell viability was determined fluorometrically by estimating release of lactate 
dehydrogenase (LDH) into the medium trough a LDH activity detection kit (Hospitex 
Diagnostics s.r.l., Italy). LDH is a cytosolic enzyme present in many different cell types. 
Plasma membrane damage releases LDH into the cell culture media. Extracellular LDH in 
the media can be quantified by a coupled enzymatic reaction in which LDH catalyzes the 
conversion of lactate to pyruvate via NAD+ reduction to NADH (Moran & Schnellmann, 
1996). The rate of conversion of NAD+ into NADH, by monitoring NADH autofluorescence 
at 340 nm, is proportional to the amount of LDH released into the medium, which is 
indicative of cytotoxicity.  
  After incubation period, the supernatant was extracted and fresh reaction solution 
was made by mixing 5 mL of 0.60 mM pyruvate with 15mL of 0.18 mM NADH in 
phosphate buffer (pH 7.5). After that, 40 μL of the cell-free supernatant was added to 200 
μL of fresh assay solution to initiate the reaction. The amount of LDH released into the 
media was expressed as percent of total LDH (Rolo et al., 2003). 
2.2.7 Cell viability assay – LIVE/DEAD 
Cell viability was also determined by the LIVE/DEAD® Viability/Cytotoxicity Assay 
Kit (Life technologies, Paisley, UK) by fluorescence microscopy. This kit is a quick and 
easy two-color assay to determine viability of cells in a population based on plasma 
membrane integrity. This assay discriminates live from dead cells by simultaneously 
staining with blue-fluorescent trihydrochloride to indicate double strand DNA and red-
fluorescent ethidium homodimer-1 to indicate loss of plasma membrane integrity. After 
incubation period the medium was removed and the cells were loaded with of 2 mM 
trihydrocoloride and 4 μM ethidium homodimer-1 in PBS (pH 7.2), during 30 min in the 
dark. After 30 minutes, the medium with probes was replaced by PBS. Then, cultured 
cells were analyzed thought light microscopy (NIKON Eclipse TS100) and with 
appropriated software (NIS-Elements D4.11.01, NIKON). The results were expressed as 
percent of total viable cells.   
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2.2.8 Protein extraction and BCA quantification  
After CDCA treatment cells were washed three times with PBS (pH 7.2) and lysed 
in cell lysis buffer (10 mM Tris–HCl, pH 7.5, 10 mM NaH2PO4, 130 mM NaCl, 1% Triton 
X-100). Lysates were then passed through a syringe to aid in the lysis and centrifuged at 
12 000 rpm for 10 min, at 4ºC. Then supernatant was removed for protein assays and the 
pellet was discarded. 
The bicinchoninic acid (BCA) protein quantification method was used to determine 
the concentration of protein. This method combines the well-known reduction of Cu+2 to 
copper cation (Cu+) by proteins in an alkaline medium (the biuret reaction) with the highly 
sensitive and selective colorimetric detection of the Cu+ using bicinchoninic acid. The 
purple-colored reaction product of this assay is formed by the chelation of two molecules 
of BCA with one cuprous ion. This water-soluble complex exhibits a strong absorbance at 
540 nm that is nearly linear with increasing protein concentrations over a broad working 
range (20-2000µg/mL). First, a working solution was prepared by adding 1 part of copper 
reagent to 50 parts of BCA reagent. To prepare a standard curve, a BSA (Bovine Serum 
Albumin) 1 mg/ml stock solution was prepared, following were prepared serial dilutions as 
in Table 1.  
 
Table 1 - Standard curve. 
Tube BSA dilution 
1 200 μL BCA + 25 μL H2O 
2 50 μL BSA 0.1% 
3 160 μL BSA 0.1% + 40 μL H2O 
4 150 μL tube 2 + 50 μL H2O 
5 133 μL tube 3 + 67 μL H2O 
6 100 μL tube 4 + 100 μL H2O 
The samples were diluted to fall within 20-2000 µg/mL, and 25 μL of samples 
diluted were added to 200 μL of BCA into duplicated wells in a 96 well plate. Then the 
plate was incubated at 37ºC for 30 minutes. Finally the absorbance was measured at 540 
nm. 
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2.2.9 Cytochrome c oxidase activity 
 Cytochrome c oxidase (COX) activity of cultured cells was polarographically 
determined by oxygen consumption using an oxygraph respirometer (Hansatech 
Instruments Ltd, Norfolk, England), as previously described by Brautigan and coworkers 
(Brautigan et al., 1978). Mitochondrial electron transport has as final step the reduction of 
O2 to water (at complex IV, cytochrome c oxidase), which can be evaluated by 
respirometry. Reduced 0.5 mM tetramethyl-p-phenylenediamine (TMPD) served as an 
electron donor to cytochrome c, and its concentration was held constant by the addition of 
2 mM ascorbate. Auto-oxidation of ascorbate and TMPD is a function of oxygen pressure 
and was subtracted from the measured oxygen consumption as a chemical background 
(Gnaiger* et al., 1998). Reactions were performed at 25°C in a closed chamber reaction 
and thermostated, with 500 μL of a mixture with PBS (pH 7.2), 2 µM rotenone, 10 µM 
cytochrome c and 150 μg of protein. After addition of protein, the reaction was initiated 
with the addition of 5 mM of ascorbate + 0.25 mM of TMPD and data were recorded 
during 4 minutes.  
2.2.10 Western blotting analysis   
 After protein extraction and quantification, samples were diluted in equal volume of 
Laemmli buffer (Bio-Rad) supplemented with β-Mercaptoethanol 5%. Equal amounts of 
protein were loaded and electrophoresed on SDS-polyacrylamide gel and transferred to a 
polyvinylidene difluoride membrane (Bio-Rad Laboratories). Membranes were blocked 
with 5% non-fat milk (Bio-Rad) and incubated with anti-COX I (1:100), anti-COX IV 
(1:1000), anti-UCP1 (1:500), anti-Caspase3 (1:1000), anti-α-tubulin (1:1000) and anti-β-
actin (1:2500). Immunodetection was performed with WesternDotTM 625 goat anti-rabbit or 
goat anti-mouse western blot kits (Life Technologies). Membranes were imaged using 
Bio-Rad Gel DocTM EZ Imager equipment and with aid of Image Lab 4.1 Bio-Rad software. 
Antibodies utilized are summarized in Table 2. 
Table 2 - List of utilized antibodies for Western blot: source, reference and dilution. 
Antibody Supplier Reference Dilution 
β-Actin Santa Cruz Biotechnology sc-47778 1:2500 
Cox I Abcam Ab14705 1:100 
Cox IV Abcam ab14744 1:1000 
Caspase 3 Cell Signaling Asp175 1:500 
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UCP1 Abcam ab10983 1:500 
α-Tubulin Sigma-Aldrich T6199 1:1000 
 
2.2.11 RNA isolation and genetic expression evaluation by qPCR 
RNA was isolated from cultured cells with resource to PureLinkTM RNA Mini Kit 
(Life technologies). First, the culture medium was aspirated and the lysis and 
homogenization of cells was done through addition of 600 μL at each well of a fresh 
solution of Lysis Buffer with β-mercaptoethanol. Then wells were scraped and the 
suspension was transferred to a 1.5 mL eppendorf and passed through a syringe. Then 
RNA purification was completed following to kit instructions, through a column-based 
method. Total RNA yield was quantified in Qubit® 2.0 Fluorometer (Life Technologies) 
and cDNA was produced using 0.75 μg of RNA with a Bio-Rad iScriptTM cDNA synthesis 
kit and Bio-Rad MyCyclerTM Thermal cycler equipment. Gene expression was evaluated 
by real-time PCR, in a Mini Opticon (Bio-Rad), using a SYBRGreen SuperMix (Bio-Rad). 
Primers used and theirs sequences are described in Table 3.  
Table 3 – Utilized primers and their respective nucleotide sequence.  
Gene Forward Primer Reverse Primer 
18S GCCCGAGCCGCCTGGATAC CCGGCGGGTCATGGGAATAAC 
COX III TCATCGTCTCGGAAGTCTTTTT ATTAGTAGGGCTTGATTTATGTGG 
COX IV AGAAGGCGCTGAAGGAGAAGGA CCAGCATGCCGAGGGAGTGA 
CPT1α GCAGCTCGCACATTACAAGGACAT AGCCGTCCCCGCCACAGGACACATAGT 
FAS GGCTGCCTCCGTGGACCTTATC GTCTAGCCCTCCCGTACACTCACT 
Glut4 ACCGGCTGGGCTGATGTGTCT GCCGACTCGAAGATGCTGGTTGAATAG 
PEPCK GGCAGCATGGGGTGTTTGTAGGA TTTGCCGAAGTTGTAGCCGAAGAAG 
PGC-1α CCCAAAGGATGCGCTCTCGTT TGCGGTGTCTGTAGTGGCTTGATT 
PPARα TGCGCAGCTCGTACAGGTCATCAA CCCCCATTTCGGTAGCAGGTAGTCTTA 
PPARγ GGCGAGGGCGATCTTGACAGG GGGCTTCCGCAGGTTTTTGAGG 
TFAM AGGAGCTGAAGGCATGCGGTGAAG GTCCAGTGCGTGCGGGTGAAC 
UCP1 CACGGGGACCTACAATGCTTACAG GGCCGTCGGTCCTTCCTT 
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2.2.12 NMR analysis  
 Nuclear magnetic resonance (NMR) spectroscopy has been used to study 
triglyceride metabolism in 3T3-L1 cells incubated with isotopically labeled compounds.  
Indeed, after cells are totally differentiated, the 96h treatment was induced but the 
medium was replaced by DMEM with 10% FBS supplemented with 1 mM [U-2H5] glycerol 
(Cortecnet) and 25 mM [U-13C] glucose (Cambrige Isotope Laboratories), with exactly 
same concentrations of CDCA. The rate of endogenous TG lipolysis was measured from 
the rate of appearance of non-deuterated glycerol in the medium and cell extracts as 
determined by 1H NMR spectroscopy. The rate of FFA esterification to TG was assessed 
by quantifying the appearance partially protonated glycerol-TG by 1H NMR spectroscopy 
of cell lipidic extracts. Glycerol synthesis from glucose and glyceroneogenesis from lactate 
was quantified by 13C-isotopomer analysis of glycerol-TG present in cells lipidic extracts.  
 Aqueous soluble metabolites were extracted from 3T3-L1 cells using a previously 
published method (Dettmer et al., 2011). After treatment period cells were washed with 
PBS (pH 7.2) twice and loaded with 750 μL of a ice-cold solution of 80% methanol and 
20% water (MeOH/H2O 80:20), as extraction solvent, which caused protein precipitation 
and hence cell disruption. Wells were then lightly scraped using a rubber tipped cell 
scraper (Armin Baack, Schwerin, Germany) and the suspension transferred to a 2 mL 
eppendorf tube. The wells were washed one more time with 750 μL ice-cold MeOH/H2O 
and the wash solution was added to the extract. The cell suspension was centrifuged at 
5725×g and 4 °C for 5 min and the supernatant was transferred to a new eppendorf tube, 
corresponding to aqueous phase. The sample was lyophilized and kept in an excicator 
until being dissolved in the adequate solvent (200 μL of 10 mM sodium fumarate 
phosphate buffered 2H2O (99.9%) solution) for NMR analysis. 
 In a second phase, was added to the pellet 1 mL of Methanol/chloroform/water 
1:1:0,1 (MeOH/CHCl3/H2O), this mixture generates a mono-phase that carries the 
advantage that cell debris can be spun down and is not located in the interphase between 
chloroform and water. The suspension was centrifuged at 5725×g and 4 °C for 5 min and 
the supernatant was transferred to a new tube, corresponding to organic phase. This 
sample was also lyophilized and kept in an excicator until being dissolved in 600 μL 
deuterated chloroform plus 25 mL a solution of pyrazine in chloroform used as internal 
standard, for evaluation of lipid absolute contents. 
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 Finally was added to pellet 200μL 8M Urea at room temperature overnight.  In the 
next day, the samples were sonicated at 3W for 20s using the Sonicator 3000 (Misonix 
Inc., Farmingdale, USA), to avoid protein aggregates, and was added 600μL of lysis buffer 
supplemented with a cocktail of protease and phosphatase inhibitors. Then was quantified 
the protein by BCA quantification, described in section 2.3.8.  
Proton (1H) NMR spectra of aqueous extracts: 1H NMR spectra of cell aqueous 
extracts were acquired on a 14.1 Tesla Varian spectrometer using a 3mm broadband 
NMR probe. Each spectrum consisted of 32k points defining a 7.2 k spectral width. A 
radiofrequency observe pulse of 30º was used and an interpulse delay of 10 seconds was 
allowed in order to warrant full relaxation of all nuclei in the sample. A total of 128 scans 
were averaged to provide adequate signal-to-noise ratios. Before Fourier transformation 
each FID (“Free Induction Decay”) was multiplied by a 0.2 HZ Lorentzian to improve 
signal/noise ratios.This spectrum allows the observation of all intracellular aqueous 
soluble metabolites and is crucial for an evaluation of the cytosolic redox (measured 
through the ratio of lactate/alanine) and for detection of the appearance of unenriched 
glycerol. Metabolic compartmentation issues can also be addressed through the 
comparison of the 13C enrichments of lactate and alanine pools and glutamate and 
glutamine pools. 
Carbon 13 (13C) NMR spectra of aqueous extracts: 13C NMR spectra of cell 
aqueous extracts were acquired on a14.1 Tesla Varian VNMRS spectrometer using a 
3mm broadband NMR probe. Each spectrum consisted of 131 k points defining a 37 kHz 
spectral width. A radiofrequency observe pulse of 45º was used and an interpulse delay of 
3 seconds was allowed in order to warrant full relaxation of all aliphatic carbon nuclei in 
the sample. The number of averaged scans ranged from 5k to 20k to provide adequate 
signal-to-noise ratios towards a 13C NMR isotopomer analysis. Before Fourier 
transformation each FID was multiplied by a 0.5 HZ Lorentzian apodization function to 
improve signal-to-noise ratios. Easily observed metabolites included lactate, alanine, 
glutamate and glutamine, as well as other metabolic intermediates from the krebs cycle 
and metabolites in exchange with these. A 13C-isotopomer analysis of glutamate provides 
information on Krebs cycle kinetics. The glutamate C4 resonance, composed by a doublet 
(D45) and a quartet (Q), correlates intimately with tissue oxygen consumption rates and 
through its analysis one can easily appreciate how effective is oxidative metabolism in the 
cells. Higher ratios of C4Q/C4D45 are concurrent with a higher rate of Krebs cycle flux 
and denote a more oxidative phenotype. In condition of higher contributions from unriched 
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sources to the acetyl-CoA pool, there is a dilution of 13C labeling in krebs cycle 
intermediates and multiply labeled isotopomers are less abundant, easily appreciated 
from the lowering in the C4Q/C4D45 multiplet ratio. 
Proton (1H) NMR spectra of cell lipidic extracts: 1H NMR spectra of lipidic 
extracts were acquired on a 11.7 Tesla Brucker spectrometer using a 5 mm Broadband 
NMR probe. Each spectrum consisted of 65k points defining a spectral width of 6 kHz. A 
radiofrequency observe pulse of 30º was used and an interpulse delay of 10 seconds was 
allowed in order to warrant full relaxation of all nuclei in the sample. A total of 128 scans 
were averaged to provide adequate signal-to-noise ratios. Before Fourier transformation 
each FID was multiplied by a 0.2 Hz Lorentzian to improve signal/noise ratios. From these 
spectra it is possible to evaluate the incorporation of partially protonated glycerol, denoting 
incorporation of glycerol deuterated provided in the culture medium in TGs. The higher the 
ratio between partially protonated and non-deuterated glycerol the more active is the 
“futile” cycle of synthesis and degradation of TGs. 
Carbon (13C) NMR spectra of cell lipidic extracts: 13C NMR spectra of lipidic 
extracts were acquired on a 11.7 Tesla Brucker spectrometer using a 5 mm Broadband 
NMR probe. Each spectrum consisted of 33k points defining a spectral width of 25 kHz. A 
radiofrequency observe pulse of 30º was used and an interpulse delay of 3 seconds was 
allowed in order to warrant full relaxation of all aliphatic carbons in the sample. A total of 
5-15k scans were averaged to provide adequate signal-to-noise ratios. Before Fourier 
transformation each FID was multiplied by a 0.5 Hz Lorentzian to improve signal-to-noise 
ratios. From these spectra it is possible to evaluate the abundance of uniformly 13C 
enriched glyceryl (Triplet, T) and doubly 13C enriched glyceryl ([2,3-13C2]glyceryl) 
(Doublet, D). The ratio D/T will be higher in conditions of higher rates of 
gliceroneogenesis. 
2.2.13 Statistical analysis 
Data is presented as Average ± SEM. Statistical significance was evaluated by use 
one-way ANOVA with Bonferroni post-hoc test (for 3 or more groups comparison) 
(GraphPad Prism, GraphPad Software Inc., San Diego, CA). A p value < 0.05 was 
considered statistically significant.  
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3. Results 
3.1 Cell death/viability  
3T3-L1 cells viability was assessed in order to evaluate if the concentrations used 
caused cytotoxicity. As shown in figure 16, 3T3-L1 cells exposure to CDCA did not induce 
an increase in described ethidium homodimer-1 staining, excluding loss of plasma 
membrane integrity caused by CDCA exposure (Figure 17).   
 
 
 
 
 
 
Figure 16 - 3T3-L1 cell death/viability after CDCA exposure. 
3T3-L1 cells were cultured as described in Chapter 2. CDCA was added for 96h and Live/Dead assay was 
performed. Data are means ± SEM of four different experiments. No statistically significant differences 
were found (P < 0.05). 
 
 
Figure 17 - Fluorescence microscopy images of 3T3-L1 cells treated with 10 μM CDCA and 50 μM CDCA 
for 96h.  
3T3-L1 cells were exposed to CDCA and stained with trihydrochloride (blue) and ethidium homodimer-1 (red) as 
described in Chapter 2. Representative images are presented to show the viability of 3T3-L1 when exposed to 
CDCA. Scale bar, 40 μm 
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Furthermore, CDCA incubation didn‟t increase LDH release into the media, 
indicating that 96h of CDCA exposure doesn‟t induce necrotic cell in 3T3-L1 cells (Figure 
18).  
 
 
 In order to exclude the induction of programmed cell death in 3T3-L1 cells exposed 
to CDCA, caspase-3 content was determined by western blot analysis. Caspases are 
crucial mediators of apoptosis and among them caspase-3 is a downstream effector 
caspase, which in turn execute apoptosis by cleaving targeted cellular proteins (Li et al.,  
2011).  
 
Figure 18 - Effects of CDCA exposure on LDH release. 
3T3-L1 cells were cultured and treated for 96h with CDCA. Samples were collected and assayed for LDH 
release into the media and intracellular LDH using spectrophotometry, as described in Chapter 2. Data are 
means ± SEM of four different experiments. No statistically significant differences were found (P < 0.05). 
Figure 19 - Caspase-3 content evaluated by western blot analysis.  
Caspase-3 content levels in 3T3-L1 cells detected by Western Blot which were performed as described in 
Chapter 2. (A) Graphic representation of relative density of caspase-3 protein levels in 3T3-L1 cells, which were 
normalized to those of α-Tubulin. (B) Data are means ± SEM of four different experiments. No statistically 
significant differences were found (P < 0.05). 
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 No significant difference was observed in caspase-3 content between control and 
adipocytes exposed to the tested concentrations of CDCA (Figure 19), indicating that 
CDCA exposure doesn‟t cause apoptotic cell death at 96h of exposure. 
3.2 Triglycerides accumulation  
Culture of 3T3-L1 adipocytes in media containing high glucose resulted in a 
significant increase in the level of triglyceride (Wang et al., 2013). To evaluate if CDCA 
interferes with lipid accumulation, TG accumulation on 3T3-L1 cells was evaluated by oil-
red o staining after 96h treatment, as described in section 2.2.2. Cells incubated with 
CDCA showed a significantly decrease in TG accumulation when compared to control, for 
both concentrations tested, at 96h of exposure, as shown in figure 20. 
 
3.3 Mitochondrial membrane potential 
The decrease in TG content induced by CDCA could be explained by increased 
oxidative capacity, which could be related with stimulation of mitochondrial function. 
Therefore, mitochondrial membrane potential was evaluated in 3T3-L1 cells incubated 
with CDCA for 96h, by using the fluorescent dye TMRM, as described in section 2.2.3. 
This important physiologic mitochondrial parameter relates to cells‟ capacity to generate 
ATP by oxidative phosphorylation. Moreover, compromised mitochondrial energy 
 
Figure 20 - Lipid accumulation in 3T3-L1 cells after CDCA exposure. 
Cells were cultured and exposed to CDCA for 96h, and then assayed for lipid accumulation through 
colorimetric assay, as described in Chapter 2. Data are means ± SEM of seven different experiments. * 
indicates statistically significant difference versus control (P < 0.05). 
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production is a major anomaly in obesity. The results showed that CDCA did not cause 
significant alterations in mitochondrial potential, after 96h treatment for both 
concentrations tested (Figure 21).  
 
 
3.4  ROS generation 
A pathological increase in ROS generation in adipocytes has been associated with 
obesity and it reflects an impairment of mitochondrial function. The results show that for 
both concentrations tested, 10 µM and 50 µM CDCA, ROS production is decreased 
(Figure 22) when compared to control. Despite the lower production in cells exposed to 10 
µM CDCA, the decreased was only significant in cells exposed to 50 µM CDCA. 
Figure 21 - Mitochondrial membrane potential (ΔΨ) in 3T3-L1 cells exposed to CDCA. 
Cells exposed for 96h to CDCA were used to estimate ΔΨ fluorometrically with the probe TMRM, as 
described in Chapter 2. Data are means ± SEM of nine different experiments. No statistically significant 
differences were found (P < 0.05). 
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3.5 Content in mitochondrial proteins 
To further investigate the biochemical basis for the effects of CDCA in 3T3-L1 
cells, mitochondrial protein content was evaluated.  Since CDCA treatment induced both a 
decrease in TG accumulation and ROS generation for cells exposed to CDCA, UCP-1 
content was determined.  The results showed a significant increase for cells exposed to 
50 μM CDCA (Figure 23).  
 
Figure 22 - ROS production in 3T3-L1 cells after exposure to CDCA. 
Cells were cultured and exposed to CDCA for 96h, and then assayed for ROS production fluorometrically using 
the probe DCFDA, as described in Chapter 2. Data are means ± SEM of five different experiments. * indicates 
statistically significant difference versus control (P < 0.05). 
Figure 23 - UCP-1 content evaluated by western blot analysis in 3T3-L1 cells. 
UCP-1 content levels in 3T3-L1 cells detected by Western Blot which were performed as described in Chapter 
2. (A) Graphic representation of relative density of UCP-1 protein levels in 3T3-L1 cells, which were normalized 
to those of β-actin. (B) Data are means ± SEM of four different experiments. * indicates statistically significant 
difference versus control (P < 0.05). 
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The content in two subunits (I and IV) of COX, one of the four complexes of MRC 
that promotes the proton pumping and establishes the electrochemical gradient for the 
synthesis of ATP, was also determined.   
Relatively to content of COX IV although there was a tendency to increase, a non 
statistically significant increase was observed between controls and cells treated with 10 
μM CDCA and 50 μM CDCA (Figure 24).  
 
Similarly, the analysis done to the content in COX I showed no significant increase 
for both concentrations tested, as shown in figure 25. 
 
  
Figure 24- COX IV content evaluated by western blot analysis in 3T3-L1 cells. 
COX IV content levels in 3T3-L1 cells detected by Western Blot which were performed as described in 
Chapter 2. (A) Graphic representation of relative density of COX IV protein levels in 3T3-L1 cells, which were 
normalized to those of β-actin. (B) Data are means ± SEM of four different experiments. No statistically 
significant differences were found (P < 0.05). 
 
 
Figure 25 - COX I content evaluated by western blot analysis in 3T3-L1 cells. 
COX I content levels in 3T3-L1 cells detected by Western Blot which were performed as described in Chapter 2. 
(A) Graphic representation of relative density of COX I protein levels in 3T3-L1 cells, which were normalized to 
those of α-Tubulin. (B) Data are means ± SEM of four different experiments. No statistically significant differences 
were found (P < 0.05). 
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So, taking into account this results the ratio between COX I (mtDNA encoded) and 
COX IV (nuclear encoded) was determined, since to form a functional holoenzyme with 
1:1 stoichiometry of all 13 subunits, exact coordination is essential between the two 
genomes (Dhar et al., 2013).  Furthermore, diseases such as obesity and T2DM have 
been associated to a decrease in mtDNA (Rolo & Palmeira, 2006). As shown in figure 26, 
the ratio between these proteins in not altered, in cells exposed to 10 μM CDCA and 50 
μM CDCA.  
 
 
3.6 Cytochrome c Oxidase activity 
Although Δψ and COX content were not altered by CDCA treatment, the decrease 
in ROS generation and increased UCP-1 content could be associated with increased 
activity of mitochondrial electron transport chain complexes. Therefore, COX activity was 
determined. However, no statistical significant differences were observed in cells exposed 
to CDCA, when compared to control (Figure 27). 
Figure 26 - COX I / COX IV ratio in 3T3-L1 exposed to CDCA. 
Graphic representation of COX I / COX IV ratio in 3T3-L1 cells. Data are means ± SEM of four different 
experiments. No statistically significant differences were found (P < 0.05). 
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3.7 Gene expression 
 
To further investigate if the decrease in TG accumulation was associated with 
alterations in cellular metabolic capacity, expression of genes implicated in lipid 
metabolism was evaluated. One of them was the enzyme carnitine palmitoyltransferase I 
alpha (CPT1α), an isoform of CPT1, located in the outer mitochondrial membrane and 
responsible for the transfer of long-chain fatty acids (LCFA) into the mitochondria. The 
elevated concentration of FFA in plasma characteristic of obesity and T2DM are 
associated with an inhibition of LCFA oxidation (Rasmussen et al., 2002). The mechanism 
responsible for the decrease in LCFA oxidation is still poorly understood but most likely it 
involves the inhibition of CPT1α (Rasmussen et al., 2002). Other key genes were also 
evaluated. FAS, a key enzyme for FFA synthesis, GLUT4, the main insulin-responsive 
glucose transporter, PPARα and PPARγ, key transcriptional regulators of fatty acid 
oxidation and mitochondrial oxidative capacity, respectively. Lastly, the expression of 
PEPCK a key enzyme that regulates glyceroneogenesis was also assessed, as well as 
mitochondrial genes (UCP-1, COX IV and COX III) and biomarkers of biogenesis 
mitochondrial like TFAM and PGC-1α. 
The results showed a tendency for increased expression in all genes, except COX 
III, for both concentrations, but only on PEPCK expression was statistically significant, as 
shown in figure 28. Since up-regulation of this enzyme is associated an increase 
Figure 27 - Cytochrome c Oxidase activity. 
Enzymatic activity was determined by oxygen consumption after incubation with CDCA using oxygen 
sensitive electrode,  as described in Chapter 2. Data are means ± SEM of four different experiments and 
are expressed in nAtm O/ min/ mg protein. No statistically significant differences were found (P < 0.05). 
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glyceroneogenesis, this results suggest that CDCA stimulates this pathway, which could 
be associated with increased TG/ (GL+FFA) cycle activity. 
 
 
 
 
Figure 28 - Gene expression levels per cell in 3T3-L1 exposed to CDCA. 
3T3-L1 cells were cultured and exposed to CDCA for 96h. Copy numbers for each gene were calculated 
based on standard curves and normalization was performed with respect to 18S RNA. Bars represent the 
mean ± S.E.M. for four different cell cultures. * Indicates statistically significant difference versus control (P < 
0.05). 
 
3.8 NMR analysis 
 
To evaluate if CDCA supplementation alters the TG/(GL+FFA) cycle activity, 
cultured 3T3-L1 cells were exposed to CDCA in the presence of labelled compounds, [U-
2H5] glycerol and [U-
13C] glucose, and followed their deposition by NMR. First analysis 
was to evaluate de novo lipogenesis (DNL). The synthesis of lipids from non-lipidic 
sources can be monitored by the detection of the incorporation of 13C in lipids. Acetyl-CoA 
derived from [U-13C] glucose will be enriched in both carbons of the acetyl moiety and can 
be used in the synthesis of lipids. These enriched lipids will be distinguishable from non-
enriched by 1H NMR spectroscopy due to the appearance of 13C satellites in the lipidic 
methyl (-CH3) resonance (Figure 29).  
CHAPTER III – Results 
64 
 
 
 
 
 
 
Figure 29 - 11.7 Tesla 
1
H NMR spectrum of the cell lipidic extract. 
The expansion shows the glyceryl moiety of TGs. Non-deuterated and partially protonated glycerol 
resonances are distinguishable and allow the quantification of TGs turnover.  
 
 
Through the integration of the satellites, the relative DNL is quantified and upon 
comparison with the internal standard (pyrazine) absolute measures of DNL are also 
possible. An analysis of the effect of CDCA in lipid content revealed a considerable 
reduction both at 10 and 50 μM CDCA concentrations (Figure 30). No significant 
differences were observed in terms of relative DNL contributions (~20% in each 
experimental condition), however absolute measures of DNL show that the addition of 
CDCA leads to a significant reduction in absolute lipid synthesis and, concomitantly, the 
overall de novo synthesis of fatty acids (DNL) is also reduced. 
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Figure 30 - 11.7 Tesla 
1
 H NMR spectrum of the cell lipidic extracts. 
The expansions show the lipidic resonances (methyl and methylenic) and clearly demonstrate a reduction in 
lipid content due to CDCA treatment. 
 
The incorporation of [U-2H5] glycerol in lipids is accompanied by the liberation into 
the media of unenriched glycerol. Thus an analysis of the deuterium enrichment of the 
glyceryl moiety of the TGs pool is the clearest evidence of the occurrence of a “futile” 
cycle of TG synthesis and degradation. Figure 31 shows the expansions of the glyceryl 
moiety of TGs for each of the experimental conditions. 
A partial protonation of the [U-2H5] glycerol at the level of triose phosphate 
isomerase (TPI), due to incorporation from H2O protons, allows its monitoring by 
1H NMR 
spectroscopy. A measure of this contribution to total glyceryl in TGs allows the monitoring 
of lipolysis followed by re-esterification. Thus, the more pronounced the turnover of the 
TGs pool the more extensive is the substitution of [U-1H5] glycerol by the partially 
protonated glycerol. With the increase in CDCA there is an increment in such contribution 
and more dynamic is the “futile” cycling. 
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Figure 31 - Expansions of the glyceryl moiety of TGs 
1
H NMR spectrum.  
Partially protonated glycerol increases with CDCA treatment. 
 
In a second phase, the synthesis of glycerol from glucose (direct synthesis) and 
glyceroneogenesis (indirect synthesis) was evaluated. [U-13C] glucose can be used in the 
synthesis of glycerol. The direct synthesis produces [U-13C] glycerol while the indirect 
prompts the appearance of the doubly labelled isotopomer [2,(3)-13C2]glycerol due to the 
action of backward scrambling at the level of the symmetric dicarboxylates  
(fumarate/succinate) in the TCA cycle. By the action of pyruvate carboxylase (PC) the [U-
13C] pyruvate forms [1, 2, 3-13C3] oxaloacetate. This isotopomer of oxaloacetate can 
subsequently be converted into [2, 3, 4-13C3] oxaloacetate by the combined actions of all 
enzymes involved in the conversion of all dicarboxylic Krebs cycle intermediates. Upon 
conversion to phosphoenolpyruvate (PEP), this oxaloacetate isotopomer looses one of the 
enriched carbons and originates the [2, 3-13C2]-enrichment pattern seen in glyceryl moiety 
of TGs. The amount of doubly labelled versus uniformly labelled glycerol will provide a 
measure of glyceroneogenesis versus direct synthesis from [U-13C] glucose. 
Figure 32 shows an expansion from the 13C NMR spectra of the lipidic extract due 
to the carbons of the glyceryl moiety of TGs. The resonance due to carbon 2 of glyceryl is 
either a triplet (T), due to [U-13C] glyceryl, or a doublet (D), due to the doubly labelled 
glyceryl isotopomer. The more pronounced this last component the higher the involvement 
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of glyceroneogenesis in the whole turnover of the glycerol pool.  A higher turnover on the 
other hand suggests that lipolitic activity is more pronounced. The more reduced the TGs 
pool the more plausible is an increment in the doubly labelled pool and such could be 
used as an indirect measure of TGs turnover. This doublet component is more significant 
in the presence of CDCA both at 10 and 50 μM levels. 
 
Figure 32 - Expansions of the glyceryl moiety of TGs 13C NMR spectrum.  
Glycerol derived directly from [U-13C] glucose (T) and glycerol derived from glyceroneogenesis (D). CDCA 
treatment increases glyceroneogenesis. 
 
Lastly, the fatty acid oxidation was measured indirectly. The [U-13C] glucose 
oxidation in the Krebs cycle causes significant enrichment of cycle intermediates due to 
cycle turnover. However in the presence of non-enriched substrate competitors, there is 
considerable dilution of 13C in cycle intermediates and rates of appearance of multiple-
labelled intermediates are significantly diminished. An increased availability of FFA in 
adipocytes could favour their oxidation and in such case there should be a considerable 
dilution of 13C labelling easily appreciated from the reduction in C4Q/C4D45 ratio seen in 
glutamate C4 resonance. Figure 33 shows the 13C NMR spectrum of the aqueous cell 
extract and the expansions of the C4 resonance of glutamate. Figure 34 shows the 
expanded multiplets of C4 glutamate and C4 glutamine for each of the experimental 
conditions. 
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Figure 33 - 
13
C NMR spectrum from an aqueous extract of adipocytes, treated with CDCA 50 μM. 
Several carbons are signalled and the expanded resonance of glutamate shows the D45 and Q multiplet 
components used in the evaluation of Krebs cycle kinetics. 
 
 
 
 
Figure 34 - Expansions of C4 glutamate and C4 glutamine resonances for the three experimental 
conditions. 
There are no differences in multiplet composition between conditions but there is a significant difference 
among metabolites. Fractional 13C enrichment is higher for glutamine than glutamate, consistent with 
metabolic compartmentation issues in adipocytes. 
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Two major conclusions can be drawn from the analysis of these spectra. First, 
there is no difference in the ratios C4Q/C4D45 both for glutamate and glutamine. This 
suggests that there is no significant oxidation of unenriched fatty acids in the adipocytes in 
any of the experimental conditions. Second, the level of 13C enrichment is higher in 
glutamine than in glutamate. Ratios of C4Q/C4D45 are higher in glutamine C4 than in 
glutamate. Since glutamine is derived from glutamate, such controversial finding suggests 
the occurrence of metabolic compartmentalization within adipocytes. The fast exchanging 
glutamine pool acquires significant levels of 13C enrichment while glutamate shows a 
combination of slow and fast exchanging pools. The sizes of these pools are noticeably in 
the same order of magnitude and do not justify the differences in labelling patterns. This 
same compartmentalization issues are absent when analysing the lactate and alanine 
pools, as reported by the analysis of the 1H NMR spectra of aqueous extracts (Figures 35 
and 36), where no differences are seen in the relative fractions of 13C enrichment for each 
metabolite. 
 
 
Figure 35 - 14.1 Tesla 
1
H NMR spectrum from an aqueous extract of adipocytes. 
The expansion shows the region of lactate and alanine methyl resonances. 
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Figure 36 - Expansions of the region of lactate and alanine methyl resonances for the three 
experimental conditions. 
CDCA does not interfere in 
13
C enrichment of these two pools. 
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4.  Discussion 
Obesity is a worldwide epidemic; the WHO estimated that 400 million people were 
obese in 2005, and an increase is expected to 700 million in 2015 (Gesta et al., 2007). 
Thus, investigation on novel therapeutic targets for this condition assumes contours of 
urgency. This growing epidemic is a prelude to co-morbidities that develop as a 
consequence of this condition including hypertension, cardiovascular disease, insulin 
resistance and T2DM. Often these diseases occur together, so the term “metabolic 
syndrome” has been used to characterize this clustering of diseases (Scarpellini & Tack, 
2012; Gesta et al., 2007; Schuster, 2010).  
Obesity is associated with an excessive accumulation of TG in adipose tissue, 
resulting in enlarged and/or increased number of fat cells. While on one hand, lipid 
storage is increased in obesity, the adipose tissue inflamed also releases more FFA 
(Bray, 2004). Increased circulating levels of FFA are initially associated with increased 
rates of fatty acid oxidation in the skeletal muscle. However, the accumulation of 
metabolites from fatty acid oxidation in the cytoplasm of muscle cells (lipotoxicity) 
interferes with insulin signaling cascade and the ability to easily switch between glucose 
and fat oxidation in response to homeostatic signals (Hsieh et al., 2011). The impaired 
uptake of glucose increases plasma glucose concentration, leading to further insulin 
secretion and starting a vicious cycle with impaired regulation of energy substrate 
metabolism (Cahová et al., 2007). 
Given the involvement of mitochondria in the metabolism of fatty acids, and its vital 
importance to the cell, any change in mitochondrial function induced by accumulation of 
fat in the adipose tissue, will certainly be reflected in the function cell. Indeed, many 
studies have been conducted within this thematic. These works indicated that adipose 
mitochondrial dysfunction associated with obesity is related to a reduction in both FFA β-
oxidation and OXPHOS rates (Medina-gómez, 2012), a decrease in mitochondrial content 
(Wilson-fritch et al., 2004), an increase in ROS generation and also an inhibition of 
antioxidant enzymes such as superoxide dismutase, glutathione peroxidase and catalase 
(Wang et al., 2010; Furukawa et al., 2004). Moreover, the deceleration and alterations on 
the TG/ (GL+FFA) cycle have been demonstrated in experimental models of obesity and 
diabetes (Reshef et al., 2003). However, besides of extensive research is this area 
(Cahová et al., 2007; Kusminski & Scherer, 2012; Vankoningsloo et al., 2005), still remain 
 74 
 
some doubts about primary site where dysregulation of mitochondrial function takes place 
and furthermore an efficient therapy to obesity.  
Recently BA have been receiving a great attention in the scientific community and a 
growing body of evidence suggests that BA also act as a signaling molecules and are 
involved in the regulation of energy expenditure (Ockenga et al., 2012; Watanabe et al., 
2006; Teodoro et al., 2013). Moreover, BA metabolism seems to be altered in T2DM 
patients and the manipulation of the BA pool can improve glucose metabolism, insulin 
resistance, energy homeostasis as well as lipid metabolism in such patients (Prawitt et al., 
2011; Cariou et al., 2011). Until recently, it was thought that BA promoted increase energy 
expenditure via a TGR5-mediated signalling cascade in BAT (Watanabe et al., 2006). 
However the clinical relevance of this pathway has been challenged, once neither the 
overexpression nor the absence of TGR5 in mice leads to a difference in body weight and 
the susceptibility to diet-induced obesity is gender-specific (Maruyama et al., 2006). 
Nevertheless it‟s undeniable that BA, namely CDCA, has an effect anti-obesity (Teodoro 
et al., 2013; Ockenga et al., 2012; Watanabe et al., 2006; Watanabe et al., 2004), 
however the mechanism by which CDCA exerts this actions remains unknown. As such, a 
possible hypothesis is that CDCA could affect TG/ (GL+FFA) cycle activity. It is known 
that CDCA activates both PPARα and PPARγ, two transcription factors that are involved 
in the transcription of key metabolic genes, like some enzymes of the TG/ (GL+FFA) cycle 
and of mitochondrial oxidative capacity (PPARγ), and of genes involved in FFA oxidation 
(PPARα). 
 In order to assess if alterations in mitochondrial function and in TG/ (GL+FFA) 
cycle are induced by CDCA, an in vitro model was chosen, 3T3-L1 adipose like cell line, 
which have been used extensively to biological research in adipose tissue (Green & 
Meuth, 1974). 
 Since it is known that CDCA are particularly hepatotoxic (Rolo et al., 2003), 
cytotoxic assays were conducted in 3T3-L1 cells. Previously studies have been conducted 
in different types of cell cultures to understand the mechanisms involved in CDCA injury 
(Park et al., 2013; K. Ramaesh & Madigan, 1998; Powell et al., 2001; Rolo et al., 2003), 
but never in 3T3-L1 adipocytes cell line. Both concentrations tested, 10 μM and 50 μM 
CDCA, did not alter both necrotic (Figure 16,17,18) and apoptotic parameters (Figure 19), 
contrarily to what has been demonstrated by previous studies in other cell lines (Park et 
al., 2013; Powell et al., 2001; K. Ramaesh & Madigan, 1998; Rolo et al., 2004).  
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 3T3-L1 adipocytes incubated with CDCA showed a significant decrease in TG 
accumulation, about 20%, when compared to control for both concentrations tested 
(Figure 20). These results are in agreement to other works realized in vivo (Cipriani et al., 
2010) that observed that CDCA leads to a significant reduction in the weight of epididymal 
WAT and subcutaneous WAT, as well as interscapular BAT, indicating a decrease in 
adiposity in conditions of diet-induced obesity (Teodoro et al., 2013).  
Impaired mitochondrial function, which includes decreased capacity to generate 
ATP and increased ROS production, are major anomalies in obesity (Vankoningsloo et al., 
2005). Therefore, stimulation of mitochondrial oxidative capacity has been associated with 
improved WAT metabolic flexibility and decreased obesity in both humans and rodents 
(Teodoro et al., 2013). Although exposure to CDCA did not cause significant alterations in 
mitochondrial potential for 96h treatment for both concentrations tested (Figure 21), ROS 
production was decreased but was only significant in cells exposed to 50 µM CDCA 
(Figure 22). This suggested a CDCA effect at a mitochondrial level. A possible 
explanation to the decrease in ROS generation and TG accumulation, could be an 
increase in UCP-1 content and activity, since a previously study in vivo demonstrated that 
CDCA increases UCP-1 content in an animal model obesity (Teodoro et al., 2013). The 
increase in UCP-1 content induced by CDCA in our cell model (Figure 26) and its impact 
on TG content is further supported by data showing that a increase in chemical 
uncoupling in 3T3-L1 cells leads to a reduction of about 35% in TG accumulation (Si et al., 
2009; Si et al., 2007; Senocak et al., 2007).  
Surprisingly, UCP-1 mRNA levels in cells exposed to CDCA were not significantly 
increased by this concentration. Based on previously evidences (Jacobsson et al., 1987; 
Patel et al., 1987; Picó et al., 1994), this seems to be related to the fact that the effect of 
stimulus on UCP-1 mRNA levels is very rapid, which in turn implies that the turnover of 
UCP-1 mRNA is also very rapid. Moreover, a recent study demonstrated that amount of 
UCP-1 is directly proportional to thermogenesis, and this apparent lack of relationship 
between UCP-1 mRNA levels and UCP-1 protein levels is explained by the fact that half-
life of UCP-1 protein (3-6 days) is much greater than half-life of UCP-1 mRNA (few hours) 
(Nedergaard & Cannon, 2013). Assuming that UCP-1 functions in 3T3-L1 adipocytes are 
similar to brown adipocytes, it should decrease the Δψ, at least in the short term (Floryk et 
al., 1999). A decrease in Δψ should decrease ATP synthesis and/or cause the reversal of 
the ATP synthase, both of which would impair the mitochondrial ATP generation. 
However, a previous study in 3T3-L1 adipocytes demonstrated that this increase in UCP-1 
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reverses the ATPsynthase activity leading to ATP hydrolysis and the transport of protons 
out of the inner mitochondria (Si et al., 2007). This proton efflux, which contributes to the 
membrane gradient at the expense of ATP, could explain the apparent lack of difference 
between the Δψ of cells exposed to 50 μM CDCA and control, observed in our study. On 
the other hand, brown adipocytes can compensate for the decrease in Δψ by up 
regulating β-oxidation and the TCA cycle, to generate extra NADH and FADH2 for 
OXPHOS (Senocak et al., 2007). Since mitochondrial mass and oxidative capacity require 
activation of both nuclear and mitochondrial-encoded genes (Palmeira et al., 2007), COX 
content was determined. The content in both proteins increased for 10 μM and 50 μM 
CDCA (Figure 23, 24) wasn‟t statistically significant; and the nuclear and mitochondrial 
genomes seemed to be perfectly regulated since the ratio is approximately 1 (Figure 25). 
qPCR analysis showed increased expression of COX IV and of two biomarkers of 
mitochondrial biogenesis, PGC-1α and TFAM (Figure 28). To understand if the increased 
content and mRNA levels of these mitochondrial biomarkers would be representative of 
an increase in oxidative capacity, COX activity was assessed. The results showed no 
difference between control and cells exposed do CDCA. Based on these results seems 
that CDCA do not affect MRC activity. Moreover seems that these cells in spite of 
expressing UCP-1 do not behave as brown adipocytes. 
Since this work aims to understand if CDCA regulates the TG/ (GL+FFA) cycle, the 
expression of genes involved in this cycle was determined. The most notable differences 
were in the expression of PPARα, PPARγ, GLUT4 and PEPCK in cells exposed to 50 μM 
CDCA, being significant in the latter (Figure 28). So contrarily to what been demonstrated 
by Kazuyuki Y. and colleagues in hepatocytes (Yamagata et al., 2004), our results 
demonstrated that CDCA increase significantly activity of PEPCK in adipocytes. This 
suggests that glyceroneogenesis, FFA re-esterification, and lipid deposition is augmented 
in these cells (Franckhauser et al., 2002). Furthermore, we demonstrated that expression 
of GLUT4 and PPARγ is also increase in 3T3-L1 in presence of 50 μM CDCA, as 
previously demonstrated by Shen and colleagues (Shen et al., 2008). The role of GLUT4 
in obesity and T2DM is still unclear, however it is known that is downregulated in this 
conditions, and over-expressing of this receptor leads to an enhance disposal and 
tolerance in adipose tissue (Shen et al., 2008; Cariou et al., 2006; Vankoningsloo et al., 
2005).  
Taking into account these results, we could say that glyceroneogenesis is 
increased, since PEPCK activity correlates directly with its expression level (Ellero-
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Simatos et al., 2011). This situation leads to an augmented in glycerol-3-phosphate 
availability and consequently in FFA re-esterification (Franckhauser et al., 2002; Olswang 
et al., 2002). This is consistent to the increase in PPARγ and FAS, since up-regulation of 
these genes stimulates enzymes involved in FFA uptake and TG synthesis, respectively 
(Vidal-Puig et al., 1996; Guan et al., 2002b; Olswang et al., 2002). However, the observed 
decrease in TG accumulation in cells treated with CDCA (Figure 20), suggests that 
despite of lipid deposition being favored, these lipids are being consumed. The augment 
in PPARα expression corroborates with this hypothesis, since this factor when co-
expressed with PGC-1α, induces the expression of FFA oxidation enzymes in 3T3-L1 
cells (Vega et al., 2000); and when rats are exposed to a PPARα activator, the expression 
of genes involved in FFA uptake and β-oxidation are increased (Christodoulides & Vidal-
Puig, 2010). Moreover the slightly increase in CPT1α seems to be also in agreement with 
a possible increase in β-oxidation.  
In order to confirm these results, TG/ (GL+FFA) activity was followed by NMR 
through deposition of labeled compounds, [U-2H5] glycerol and [U-
13C] glucose. Firstly, 
DNL was evaluated, since elevated synthesis of lipids is associated to obesity (Wang et 
al., 2013; McDevitt et al., 2001). Our results demonstrated no significant differences in 
terms of relative DNL contributions (~20% in each experimental condition), however 
absolute measures of DNL show that the addition of CDCA leads to a significant reduction 
in absolute lipid synthesis and concomitantly the overall de novo synthesis of fatty acids is 
also reduced (Figure 30). On the other hand, an increase in lipolysis followed by re-
esterification of FFA was observed, i.e. a more pronounced turnover of the TG, in 
presence of CDCA. This demonstrates that there is an increment in the “futile” cycling 
(Figure 31), which is decreased in situations of obesity and T2DM (Prentki & Madiraju, 
2008; Prentki & Madiraju, 2012; Reshef et al., 2003). To further this idea, 
glyceroneogenesis is increased in presence of CDCA, based either in increase of PEPCK 
expression (Figure 28) as in the increase of the doubly labelled glyceryl isotopomer in TG 
pool of cell lipidic extracts (Figure 32).  
Thus, this increase in TG/ (GL+FFA) activity, leads to an augmented availability of 
FFA in adipocytes, which could favor their oxidation. However there is no significant 
oxidation of unenriched fatty acids in the adipocytes in any of the experimental conditions 
(Figure 34). This might be a surprising result assuming the higher TG turnover (Figure 
31), the increase in PPARα expression (Figure 28) and the reduction in TG accumulation 
(Figure 20), seen in CDCA treated cells. However one must consider the fact that these 
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cells are specialized in lipid synthesis and not in lipid degradation/oxidation (Large et al., 
2004). The reduction in lipid content can thus only be explained by their export to the 
medium. 
Another surprising conclusion is that ratios of C4Q/C4D45 are higher in glutamine 
C4 than in glutamate (Figure 34). Since glutamine is derived from glutamate, such 
controversial finding suggests the occurrence of metabolic compartmentation within 
adipocytes, i.e. distinct intracellular pools of glutamine and glutamate that are not in 
equilibrium, as previously demonstrated (Patel et al., 1982). The sizes of these pools are 
noticeably in the same order of magnitude and do not justify the differences in labelling 
patterns. Further studies will be required to shed some light into these compartmentation 
issues but their interest is undoubtedly warranted by the inimitability of its behavior. This 
same compartmentation issues are absent when analysing the lactate and alanine pools 
(Figure 34 and 36). 
 Concluding, there are three major conclusions that can be drawn: 1) CDCA leads 
to a decrease in TG accumulation in 3T3-L1 adipocytes; 2) CDCA leads to an increase in 
UCP-1 content; 3) CDCA leads to an increase in glyceroneogenesis that consequently 
leads to an increase in TG/ (GL+FFA) cycle activity. Indeed, these results show that 
administration of CDCA seems to be an attractive therapy to obesity and T2DM. On the 
other hand, a question still remains, what leads to a reduction in TG accumulation? CDCA 
up-regulates genes involved in β-oxidation and mitochondrial biogenesis, but there are no 
differences in fatty acid oxidation between control and cell exposed to CDCA. A possible 
explanation is that lipids are being exported to the medium. However this is an in vitro 
study, it would be interesting understand the destination of this lipids in vivo. Finally the 
possible occurrence of metabolic compartmentalization opens new perspectives in futures 
works.  
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